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IDENTIFYING GENETIC VARIANTS ASSOCIATED WITH MULTIPLE 
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JACQUELINE N. MILTON 
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ABSTRACT 
Sickle cell disease is a monogenic blood disorder in which the clinical course and disease 
severity vary widely among patients.  In order for physicians to make more informed 
decisions regarding the treatment and management of disease, it would be useful to be 
able to predict disease severity.  We focus on two primary modulators of disease severity 
in sickle cell patients, hemolysis and fetal hemoglobin (HbF).  This dissertation evaluates 
methodology to identify genetic variants associated with severity of sickle cell disease 
and develops new methodology of genetic risk prediction to predict disease severity in 
sickle cell patients based on levels of HbF.   
Hemolysis is a trait that is influenced by multiple correlated phenotypes (lactate 
dehydrogenase, reticulocytes, bilirubin and aspartate transaminase).  There are several 
approaches to statistical analyses of multiple correlated phenotypes. The first part of this 
dissertation evaluates the use of principal component analysis (PCA) and compares it to 
the alternative approach of examining the results of multiple univariate phenotypes 
individually.  We will focus on the question of if and under what conditions we gain 
more power using a summarized phenotype from PCA in a genome wide association 
 
 
 vii 
study (GWAS) rather than conducting multiple individual GWAS.  We find that the there 
is more power gained from the PCA approach when there is a strong intercorrelation 
between the phenotypes.  
The second part of this dissertation proposes a novel method of genetic risk prediction for 
continuous traits using an ensemble of genetic models.  We aim to show through a 
simulation and prediction of HbF that the proposed method is more robust to the 
inclusion of false positives and yields more stable predictions than computing a GRS and 
10 fold cross validation.  
The third part of this dissertation introduces a Bayesian-based clustering approach to 
produce clusters of sickle cell anemia patients based on their “predicted genetic profiles” 
of HbF.  We then examine the genetic profiles of individuals in the extreme clusters to 
determine which genes contribute more prominently to the genetic profile so that we may 
potentially identify genes that are highly influential in the regulation of extremely high 
and low values of HbF. 
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1 Introduction 
 Oftentimes individuals have genetic variants that influence the outcome and 
severity of a disease.  One of the aims of genome-wide association studies (GWAS) is to 
identify genetic modifiers and possibly use this information to predict disease or disease 
severity.  Since a GWAS involves genetic variants from the entire genome, it is a non-
biased approach to identifying regions associated with disease/disease severity.   
 In some studies the phenotype of interest is influenced by multiple correlated and 
observable traits.  When this occurs, there are multiple approaches to statistical analyses: 
using a random effects model to account for the correlation between the traits 1; 2, running 
multiple univariate tests (one for each trait) and combining the test statistics 3; 4, or 
creating a summary phenotype from the correlated traits 5; 6.  Another common approach 
to statistical inference in this situation is to model each outcome separately ignoring the 
potential correlation among the responses7.  This strategy may be less efficient in that it 
ignores the extra information contained in the correlation among the outcomes.   
 Creating a summary phenotype via a principal component analysis (PCA) has 
been evaluated in the context of a quantitative trait loci (QTL) linkage analysis; however, 
the method of using the intersection of the results from univariate GWAS has not and the 
two methods have not been compared 8; 9.  This is one of the questions we address in this 
thesis. 
 Statistical advantages of performing joint analysis of correlated traits include 
increased power to detect loci and increased precision of parameter estimation 1; 10.  
Biological advantages of performing joint analysis of correlated traits include the ability 
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to address the issue of pleiotropy (one locus influencing multiple correlated traits) vs. 
tight linkage (linked loci each influencing one of the traits) as well as the ability to 
investigate endophenotypes11-14 intermediate between a gene and a trait. 
1.1 Principal Component Analysis 
 PCA is an established approach to summarize correlated traits into a summary 
phenotype for GWAS.  PCA seeks to identify a linear combination of the correlated 
variables that will explain the most variability of the data.  The PCA reduces the 
dimension of the data by summarizing the variability of the data into principal 
components (PCs).  The first PC will explain the largest proportion of variability in all of 
the traits analyzed and each consecutive PC will explain less and less variability.  In a 
GWAS setting, the first PC can be used as the phenotype for analysis if it explains a large 
proportion of the variability of the phenotypes.   
1.2 Univariate Tests 
 Another approach to identifying genetic variants associated with a phenotype 
influenced by multiple correlated traits is to perform a GWAS for each individual trait 
and examine the intersection of the top results.  A pre-determined type I error threshold is 
used to identify genetic variants associated with each individual trait.  The genetic 
modifiers that reach the type I error threshold for all individual traits are deemed to be 
significantly associated with the phenotype.  The issue that arises with this type of 
analysis is that oftentimes using a strict type I error rate yields very few significant 
results.  However, lowering the type I error rate can lead to false positives. 
 The second chapter of this thesis proposes to compare principal component 
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analysis and univariate tests to identify genetic variants associated with a phenotype that 
is influenced by multiple traits in a real life example and through simulation studies.  We 
hypothesize that when performing a GWAS on a summary phenotype (the 1st PC) we 
will gain more power to detect genetic variants that are associated with multiple 
correlated traits in comparison to examining the intersection of the univariate analyses. 
1.3 Genetic Risk Prediction 
 Another aim of GWAS is to identify single nucleotide polymorphisms (SNPs) 
that will aid in phenotype prediction.  Oftentimes in GWAS there are highly significant 
associations between genetic variants and the phenotype of interest; however, the 
variability explained by these variants is often quite small.  The computation of a genetic 
risk score (GRS) is an established method used to combine individual SNPs to aid in 
phenotype prediction when a multivariable model includes too many genetic variants 15-20 
.  The results of a GWAS are used to build the GRS model.  SNPs are sorted by 
increasing p-values, starting from the most significant SNP, an unweighted GRS is 
computed by cumulatively adding the number of risk alleles for each SNP: 
 
𝐺𝑅𝑆!,! =    𝑅𝑖𝑠𝑘  𝐴𝑙𝑙𝑒𝑙𝑒!,!!!!!  
where Risk Allelei,j is the number of risk alleles an individual i has for jth SNP in the 
GRS.  We then compute n predicted phenotypes for each individual i as follows: 𝑌!,! =   𝛽! +   𝛽! ∗ 𝐺𝑅𝑆!,! 
where GRSi,n is the cumulative number of risk alleles an individual i has for n SNPs in 
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the GRS.  The predictive accuracy of the model is evaluated by computing the correlation 
between the observed and predicted phenotype or by examining the amount of the 
variability explained by the GRS model in an independent dataset. 
 One of the problems with using a GRS for phenotype prediction is determining 
how many genetic variants should be included in the model.  In the third chapter of this 
thesis, we introduce a novel method of phenotype prediction which extends the GRS 
approach introduced in Sebastiani et al. 2012 for building genetic risk prediction models 
from case control studies to quantitative traits18.  We then compare this approach to the 
GRS methods and 10 fold cross validation (CV) for phenotype prediction through a real-
life example and in simulation studies. 
1.4 Clustering Genetic Profiles 
 Another aim of GWAS is to identify molecular pathways involved in the 
regulation of a phenotype.  Current methods to find molecular pathways associated with 
disease or disease severity involve using the results of the most significant genetic 
variants from a GWAS.  However, it has been shown that the top results of GWAS are 
not always sufficient to predict of disease severity.  Genetic variants that don’t reach 
genome-wide significance may also be useful in identifying molecular pathways 
associated with disease.  Generating genetic profiles is an established approach to 
identify variants involved in disease classification and molecular pathways of disease19.  
Genetic profiles involve determining combinations of genetic variants that are associated 
with disease classification or phenotype.  The fourth chapter of this thesis introduces a 
novel method of generating genetic profiles called “predicted genetic profiles” and the 
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utilization of Bayesian model based clustering to produce clusters of these “predicted 
genetic profiles”.  Our goal is to examine the genetic profiles of individuals in extreme 
clusters to determine which genes/genetic variants contribute more prominently to the 
genetic profile so that we may potentially identify novel molecular pathways involved in 
the regulation of our phenotype. 
1.5 Summary 
 This thesis is divided into the following chapters.  Chapter 2 evaluates two 
methods used to identify genetic variants associated with a phenotype influenced by 
multiple correlated traits through both a real life example and simulation21; 22.  We show 
that using a PCA to compute a summary phenotype provides more power to detect 
genetic variants that are associated with correlated traits in comparison to studying the 
intersection of multiple univariate tests with a most increase of the false positive rate.   
 In Chapter 3, we introduce a novel method of genetic risk prediction of a 
continuous trait.  The algorithm involves computing an ensemble of GRS models, which 
combines multiple GRS models to generate a prediction of the phenotype.  We predict 
fetal hemoglobin (HbF) in sickle cell anemia (SCA) patients and compare this method of 
phenotype prediction to the regular computation of a GRS model and 10 fold CV in three 
independent cohorts.  We also evaluate the three phenotype prediction methods through 
simulation.  We show that in comparison to the usual GRS procedure and 10 fold CV, the 
ensemble of GRS models explains similar variability in the phenotype and is more robust 
to the inclusion of SNPs that are false positives.   
 In Chapter 4, we introduce a novel method of generating genetic profiles of HbF, 
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which are called predicted genetic profiles.  We generate genetic profiles of HbF for SCA 
patients based on their predicted values computed using an ensemble of GRS models. We 
then examine the approach of Bayesian model based clustering to produce clusters of 
individuals with similar predicted genetic profiles.  We describe how this clustering can 
be used to provide information on the genetic variants that contribute the most to the 
predicted genetic profiles, which could provide insight into genes that may influence HbF 
levels.  The strategy behind this methodology is that individuals who share similar 
predicted genetic profiles should provide information about the combination of genetic 
variants these individual have in common.  
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2 Multiple Trait Analysis 
2.1 Introduction 
 We consider the situation in which we are interested in discovering genetic 
modifiers of a trait that is defined by a combination of observable traits.  What we will try 
to answer is whether it is best to analyze the traits independently and combine the results 
or combine the traits and analyze the combination.  PCA is an approach to create a 
summary phenotype in which the 1st PC can be used as a phenotype in a GWAS.  An 
alternative solution is to examine the intersection of the top hits of each univariate test 
but this approach often yields few results when using the genome-wide significant 
threshold of 5x10-08.  However, when using a lower type I error rate this approach can 
often yield false positives.   
 Weller et al. (1996) proposed multiple analysis of univariate, uncorrelated 
eigentraits derived by eigen decomposition of the covariance matrix for the original 
traits8.  Korol et al. proposed eigen decomposition of the phenotypic covariance matrix in 
order to reduce the multiple traits into a single variable, but over short genomic intervals 
to account for the natural stratification of a sample by genotype 23.  Elston et al. 
transformed the traits to their PCs, performed univariate regression analysis on each PC, 
and then summed the squared non-negative univariate t-statistics, assuming that this sum 
asymptotically follows a mixture of χ2 distributions24.  The major limitation of these 
approaches is that it is not always possible to find a canonical transformation 
guaranteeing that all loci influence only one canonical trait. 
 In this chapter we propose to evaluate these two approaches of detecting genetic 
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variants that are associated with a phenotype (directly or indirectly observed) that is 
influenced by multiple traits.  We evaluate these two approaches through simulation and 
through application by identifying genetic variants associated with hemolysis in SCA 
patients.  Using simulation, we compare the power of detecting genetic variants 
associated with multiple traits using PCA and by examining the intersection of the top 
hits of each univariate GWAS test.  Our results suggest that when the genetic variant 
meets the genome-wide significant threshold for each of the individual traits, it will be 
detected in both methods.  However, our simulations and real-life application suggest that 
PCA has the advantage that when genetic variants do not meet the genome-wide 
significance threshold for each of the individual traits, but they show a consistent effect 
the PCA approach can provide more power to detect these genetic variants.  Overall, we 
find that there is more power to detect SNPs using the PCA approach in comparison to 
identifying significant SNPs from each univariate test and examining the intersection of 
the results with most increase in the false positive rate. 
2.2 Computation of PCs 
 To compute the PCs, the data are organized in a matrix, X, in which the rows are 
subjects (i = 1 to N) and the columns are traits (j=1 to M).  Each trait (column) in X is 
then normalized to have a mean 0 and standard deviation 1.  If we call this matrix of 
standardized columns Z, we get: 
𝑍!,! =   𝑋!,! − 𝑋!  𝑠𝑑(𝑋!)  
where Zi,j is the (i,j)th element of matrix Z. 
 The variance-covariance matrix of the traits is computed as S=ZTZ which is an 
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MxM matrix of rank at most M.  Eigenvalue decomposition is performed on S such that 
S=VD2VT, where V is a matrix in which the columns are the eigenvectors, vj, and D is a 
MxM diagonal matrix, with the diagonal entries d1 ≤ d2 ≤ dM ≤ 0 which are the singular 
values and we have: 
𝑑!! =    𝑣(𝑋!)!!!!!!!!  
The PCs are then computed as a linear combination of the traits and the eigenvectors, vj 
as follows: 
𝑦!,! =    𝑧!,! ∗ 𝑣!!!!!  
Thus we compute j = 1 to M PCs25.  
2.3 Description of Simulated Data and Applications to Real Data 
 In this section we describe how the simulated data were generated and provide 
details about the applications.  In section 2.4 we provide the results to the simulations and 
in section 2.5 we provide the results of the applications to real data. 
2.3.1 Simulated Data 
 We simulated 1,000 independent SNPs for 1,000 individuals.  The minor allele 
frequencies for each SNP range between 0.05 and 0.50.  Genotype frequencies were 
computed from the allele frequencies assuming Hardy Weinberg equilibrium, and 
individuals were randomly assigned genotypes according to the genotype frequencies.  
We then simulated 5 correlated phenoypes (y1 to y5) that were associated with 5 of the 
1,000 independent SNPs based on an additive genetic model.  We simulated the 
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phenotypes such that the effect sizes of these additive genetic models were in a consistent 
direction and ranged from 0.2 to 0.4, and we simulated scenarios in which the effects 
were not in a consistent direction and ranged from -0.4 to 0.4.  The variability of the 
phenotype ranged from low (1/4 the mean of the phenotype) to medium (1/2 the mean of 
the phenotype) to high (3/4 of the mean of the phenotype).  For simulations in which the 
effect sizes between the SNPs and the traits are consistent the distributions of the 
phenotypes are as follows where N(µ, σ2) denote a normally distributed variable with a 
mean µ and a variance σ2. 
y1~N(0.2*SNP1 +0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5, abs(0.2*SNP1 
+0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5)) 
y2~N(0.2*SNP1 +0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5, abs(0.2*SNP1 
+0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5)) 
y3~N(0.4*SNP1 +0.35* SNP2 +0.30* SNP3+0.25* SNP4+0.2* SNP5, abs(0.4*SNP1 
+0.35* SNP2 +0.30* SNP3+0.25* SNP4+0.2* SNP5)) 
y4~N(0.2*SNP1 +0.3* SNP2 +0.4* SNP3+0.25* SNP4+0.35* SNP5, abs(0.2*SNP1 +0.3* 
SNP2 +0.4* SNP3+0.25* SNP4+0.35* SNP5)) 
y5~N(0.4*SNP1 +0.35* SNP2 +0.2* SNP3+0.25* SNP4+0.3* SNP5, abs(0.4*SNP1 +0.35* 
SNP2 +0.2* SNP3+0.25* SNP4+0.3* SNP5)) 
 
Here a is equal to ¼, ½ or ¾ for low, medium and high variability of the trait.  For 
simulations in which the effect sizes between the SNPs and the traits are not consistent 
the distributions of the phenotypes are as follows: 
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y1~N(0.2*SNP1 +0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5, abs(0.2*SNP1 
+0.25* SNP2 +0.30* SNP3+0.35* SNP4+0.4* SNP5)) 
y2~N(-0.2*SNP1 -0.25* SNP2 -0.30* SNP3-0.35* SNP4-0.4* SNP5, abs(-0.2*SNP1 -0.25* 
SNP2 -0.30* SNP3-0.35* SNP4-0.4* SNP5)) 
y3~N(-0.4*SNP1 -0.35* SNP2 -0.30* SNP3-0.25* SNP4-0.2* SNP5, abs(-0.4*SNP1 -0.35* 
SNP2 -0.30* SNP3-0.25* SNP4-0.2* SNP5)) 
y4~N(0.2*SNP1 +0.3* SNP2 +0.4* SNP3+0.25* SNP4+0.35* SNP5, abs(0.2*SNP1 +0.3* 
SNP2 +0.4* SNP3+0.25* SNP4+0.35* SNP5)) 
y5~N(0.4*SNP1 +0.35* SNP2 +0.2* SNP3+0.25* SNP4+0.3* SNP5, abs(0.4*SNP1 +0.35* 
SNP2 +0.2* SNP3+0.25* SNP4+0.3* SNP5)) 
Table 1 shows the estimates of the correlations between the 5 simulated traits.   
 In addition to simulating 5 correlated traits which were correlated with 5 SNPs, 
we also simulated the above scenario while including an association between each trait 
and an environmental variable that is independent of the SNPs.  Our goal was to see how 
well each method would be able to detect all 5 SNPs with added noise added to the traits.  
To simulate this environmental variable, ENVIRON, we used a distribution of 
ENVIRON~binomial (1000, 0.3) with an effect size of 0.3 for each trait.  We also 
examined the results of a scenario where there were 4 correlated traits were simulated 
with effect sizes in a consistent direction for all 5 causal SNPs and there was one null 
trait which was not associated with any SNPs. 
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2.3.2 Project of the Comprehensive Sickle Cell Centers 
SCA patients from the Project of the Comprehensive Sickle Cell Centers were 
included as an application for comparing the methods of examining the intersection of the 
results of univariate analyses and using a PCA method to generate a summary phenotype. 
The phenotype of sickle cell anemia is caused by sickle vasoocclusion and hemolytic 
anemia 26. Hemolysis in this disease has been associated with complications that could 
result in part from vascular nitric oxide (NO) depletion due to scavenging by free plasma 
hemoglobin 27-29. Plasma hemoglobin is a specific marker of intravascular hemolysis and 
red cell survival studies are the definitive measurement of hemolysis. Nevertheless, these 
tests are rarely done and are not available in large cohorts. However, hemolysis can be 
estimated by the reticulocyte count, lactate dehydrogenase (LDH), aspartate 
aminotransferase (AST) and bilirubin levels, all of which are commonly measured in 
cohort studies, although none are specific for hemolysis 26; 30.   
 The patient cohort used for discovery consisted of 1,117 patients from the 
Cooperative Study of Sickle Cell Disease (CSSCD; NCT00005277) homozygous for the 
HbS gene or with HbS-β0 thalassaemia. Four-hundred forty-nine patients from the 
Pulmonary Hypertension and Sickle Cell Disease with Sildenafil Therapy (Walk-
PHaSST) study (NCT00492531) and 296 patients from a study of pulmonary 
hypertension in children with sickle cell disease (PUSH NCT 00495638) with similar 
hemoglobin phenotypes as the discovery set were used for replication of the discovery 
findings. The demographics of these studies have been described previously31-33.  For 
further validation, targeted genotyping was done in a third cohort of 213 additional 
patients with sickle cell disease from London, UK.   These studies were approved by the 
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Institutional Review Boards of each participating institution.  Both the discovery and 
validation cohorts included sickle cell patients of African American ethnicity. 
2.3.3 Description of Analyses 
In all applications and simulations we used the principal components analysis 
implemented in the R package princomp scaling each hemolytic component to have a 
standard normal distribution.  All GWAS used linear regression with an additive genetic 
model.  All SNPs had a call rate greater than 0.95 and a minor allele frequency (MAF) 
greater than 0.05.  Analysis were performed using the software PLINK 34. 
 We estimated the severity of hemolysis using a principal component analysis of 
the commonly measured markers of hemolysis 35; 36.  We performed a GWAS using the 
1st PC as the phenotype.  We then ran a GWAS on each of the individual hemolytic 
components and examined the intersection of the top results 21; 22.  Both analyses used an 
additive genetic model adjusting for age and gender. 
2.4 Results of Simulations 
We hypothesize that when comparing the two methods of detecting SNPs that are 
associated with multiple traits that define a phenotype using a PCA approach will yield 
more power in comparison to examining the intersection of the univariate tests.   
We examined the power and type I error rates at three different thresholds (5E-04, 
5E-06, 5E-08) using the following definitions: 
power for PCA method= p(detecting all 5 causal SNPs using summary 
phenotype) 
power for intersection method = p(detecting all 5 casual SNPs for all 5 traits) 
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type I error rate for PCA method = p(detecting any of the 995 null SNPs) 
type I error rate for intersection method = p(detecting any of the 995 null SNPs 
when examining all 5 phenotypes) 
Table 2 shows the results of the simulation study of the power for the two 
approaches where the phenotype has low, medium and high variability and the results of 
the PCA method when there were four correlated traits and one null trait.   We evaluated 
the results over 1,000 simulations. 
We see from Table 2 that as the variability of the data increases (from low to 
medium to high) the power of both methods decreases.  The power and type I error rates 
are similar when comparing models where we simulated consistent or inconsistent effect 
sizes.  We also see that there is more power in the PCA approach in comparison the 
intersection method; however, the PCA approach has a higher type I error rate.  One 
might expect this due to the fact that in order for any of the 995 null SNPs to be detected 
in the intersection method they would have to be detected for each of the 5 traits.  Using 
the PC method, we might see by chance that the 1st PC is significantly associated one of 
the 995 null SNPs due to the fact that the SNP is associated with one or two of the five 
traits.  These results are consistent when we examine simulations where we include an 
environmental variable that is also associated with the phenotype.  When we examine the 
results in which we include a null trait that is not associated with any of the four traits we 
see that we see that overall the power and type I error rates remain consistent.  This is due 
to the fact that when computing the1st PC in the models in which there is a null trait the 
factor loading for the null trait is 0.   
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Table 3 shows the simulation results with the added environmental variable.  We 
see the same trends in the results of the simulations as we do in Table 2.  One can also 
see that overall there is less power when including an environmental variable due to the 
fact that we have added more variability to the traits that is not explained by the SNPs.  
When we examine the results of including a null trait in the PCA, we see that overall the 
type I error rates are slightly lower and the power remains consistent.  This is due to the 
fact that the 1st PC is examining the variability explained by the four correlated traits.  
When examining the factor loadings of the 1st PC, the null trait has a loading of 0. 
2.5 Application to Real Data 
2.5.1 Overview of Analyses 
Based on the results of the simulations hypothesize that using a PCA summary 
phenotype will yield more power for genetic variants that are associated with phenotypes 
correlated with multiple traits and that using a univariate test will have more power to 
detect genetic variants that are trait specific (associated with only one trait).  To illustrate 
this we present the results of two GWAS, one in which the phenotype is serum bilirubin 
(section 2.4.2) 22, the other in which the phenotype is the 1st PC from a PCA using serum 
bilirubin, LDH, AST and reticulocyte count (section 2.4.3) 21. 
2.5.2 Hyperbilirubinemia in SCA Patients 
The discovery set consisted of 1,117 African American subjects from the 
Cooperative Study of Sickle Cell Disease (CSSCD) 37.  The replication cohorts were 
comprised of 195 subjects from the Multicenter Study of Hydroxyurea (MSH), 522 
subjects from the Pulmonary Hypertension and Sickle Cell Disease with Sildenafil 
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Therapy (Walk-PHaSST) study (NCT00492531) 33, 530 subjects from the Outcome 
Modifying Genes study (referred to subsequently as “Duke”) that enrolled patients from 
Duke University Medical Center, the University of North Carolina Chapel Hill, Emory 
University, East Carolina University Comprehensive Sickle Cell Centers, and the 
Carolinas Health Center, and 905 samples from the SITT silent cerebral infarct trial 
(NCT00072761).  None of the patients from the CSSCD discovery set were treated with 
hydroxyurea as recruitment for this study concluded in 1998.  To eliminate potential 
confounding effects of hydroxyurea, in the MSH, pre-hydroxyurea levels of total 
bilirubin were utilized 38.     
Serum total and direct bilirubin, lactate dehydrogenase (LDH), hemoglobin 
concentrations, and reticulocyte counts were measured using automated chemical and 
hematologic analyzers at the individual medical centers participating in these studies.  
For the CSSCD patients, longitudinal bilirubin measurements were collected from 
phases 1, 2, and 3 of the study 37. Only steady state measurements were used (4 months 
removed from blood transfusion). The longitudinal measurements of study patients were 
analyzed using a Bayesian hierarchical mixed model that included a random effect per 
patient to account for the repeated measurements, as well as random intercept and age 
effects that were allowed to vary with the clinics. The random intercept and age effects 
were used to remove the between-site differences.  
Since the data were skewed, the measurements were modeled using a lognormal 
distribution with mean, µ and variance, τ.  Specifically, the mean, µ was modeled using 
the following formula: 
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µ = β0,clinic+βclinic,age(age-mean(age)) + βclinic,sex(sex-mean(sex)) + βpatient 
where β0,clinic, βage,clinic, and βsex,clinic are clinic specific parameters and βpatient is a patient 
specific random effect to account for related measurements. 
The mean of distribution was modeled such that each clinic has a separate slope and age 
and gender effect.  The patient, age and gender random effect and intercept were modeled 
using a normal prior. 
βpatient~dnorm(0,τpatient) 
β0,clinic~dnorm(alpha.0,τ0) 
βage~dnorm(alpha.age,τage) 
βsex~dnorm(alpha.sex,τsex) 
The mean of the random effects was modeled with a normal distribution and the variance 
a gamma prior: 
alpha.0~ dnorm(200,0.0001) 
alpha.age~dnorm(0,0.0001) 
alpha.sex~dnorm(0,0.0001) 
τpatient~dgamma(1,1) 
τ0~dgamma(1,1) 
τage~dgamma(1,1) 
τsex~dgamma(1,1) 
Where α0, αage, and αsex would be the population parameters adjusted for the clinic 
effect.  Markov Chain Monte Carlo method in Openbugs was used to estimate the 
predicted total bilirubin values, and log-transformed median predicted values were used 
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as the phenotype for the GWAS.  
The Bayesian model was used to compute predicted values of each trait that were 
averaged (median value) to have one single measure to be used in the GWAS. 
 For MSH, Duke, Walk-PHaSST and SITT patients, the log transformed baseline 
total bilirubin was used.  Table 4 shows the patient characteristics for each participating 
study.  Table 5 shows the correlation between the hemolytic markers. 
Using an additive genetic model adjusting for age and gender for 569,615 SNPs, 
15 SNPs met the genome-wide significance threshold for the serum bilirubim GWAS.  
Figure 1 shows the Manhattan plot where there is a large spike of significant associations 
in chromosome 2. The quantile-quantile (QQ) plot (Figure 2) shows no inflation (lambda 
factor, λ=1.01) suggesting that there is no inflation of pvalues. To confirm this, we 
repeated the analysis after adjustment for the top ten population structure principal 
components and the magnitude and significance of the top SNPs did not change.  We 
report the results of the additive model for the 15 SNPs that met the genome-wide 
significance threshold in Table 6. 
These genes are located on a contiguous part of chromosome 2 of the UGT1 
region. This region has previously been shown to be associated with hyperbilirubinemia.  
Genetic studies of these patients have identified a dinucleotide repeat polymorphism 
(TA)5-8 in the TATA box of the UGT1A1 gene promoter that is associated with reduced 
UGT expression and produces hyperbilirubinemia39-43.  This polymorphism has also been 
observed in small cohorts of sickle cell anemia patients suggesting a common pathogenic 
link between ethnically divergent etiologies of indirect hyperbilirubinemia 44-51.  We 
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show that these genetic variants are trait specific and not related to hemolysis by 
examining the association between these SNPs and other hemolytic components (Table 
7).  None of the SNPs are significantly associated with LDH, reticulocyte count or AST. 
We show in an applied setting that there is more power to detect SNPs associated 
with trait-specific phenotypes in comparison to a summary phenotype (the 1st PC from a 
PCA). 
 
2.5.3 Hemolysis in SCA Patients   
The patient cohort used for discovery consisted of 1,117 patients from the 
Cooperative Study of Sickle Cell Disease (CSSCD; NCT00005277) homozygous for the 
HbS gene or with HbS-β0 thalassaemia. 449 patients from the Pulmonary Hypertension 
and Sickle Cell Disease with Sildenafil Therapy (Walk-PHaSST) study (NCT00492531) 
and 296 patients from a study of pulmonary hypertension in children with sickle cell 
disease (PUSH NCT 00495638) with similar hemoglobin phenotypes as the discovery set 
were used for replication of the discovery findings. The demographics of these studies 
have been described 31-33.  For further validation, targeted genotyping was done in a third 
cohort of 213 additional patients with sickle cell disease from London, UK.   These 
studies were approved by the Institutional Review Boards of each participating 
institution. 
Serum total bilirubin, LDH, AST, and reticulocyte counts were measured using 
automated chemical and hematologic analyzers.  For the PUSH and Walk-PHaSST 
patients, log transformed baseline values were used in the principal component analysis.  
Patient characteristics for the discovery, replication and validation cohorts are shown in 
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Table 8. 
Table 8 shows demographics, hematologic data, laboratory measures of hemolysis 
and the derived hemolytic score for all 4 cohorts. Males have a higher hemolytic score 
compared with females.  Participants in the Walk-PHaSST study were adults and had the 
highest mean age, patients in the PUSH study were children with the lowest mean age 
while CSSCD cases included both adults and children and had intermediate ages. There 
was a significant association between age and the hemolytic score (r =.195, 
pvalue=3.40x10-11) and this was adjusted for in the analysis. CSSCD cases did not take 
hydroxyurea, 58% of Walk-PHaSST and 44% PUSH patients were treated with 
hydroxyurea. 
The first principal component explained 67.4% of the total variance and this 
measurement was used as the hemolytic score in the CSSCD cohort.  When comparing 
the association between the hemolytic score and each of the 4 markers of hemolysis, as 
each of the 4 hemolytic markers increased the hemolytic score decreased (Figure 5).  This 
consistency of effect across the 4 hemolytic markers indicates that the first principal 
component is a good marker of hemolysis. 
The Manhattan plot summarizing the results of the GWAS is shown in Figure 4 
and the results of the most significantly associated SNPs summarized in Table 8.  The 
QQ plot in Figure 4 shows no inflation and a genomic lambda factor of 1.01 was 
calculated indicating that there is no confounding due to population stratification. 
Although no SNP met the 10-8 level of genome-wide significance, rs7203560 in NPRL3 
was associated with hemolytic score with a pvalue of 6.04x10-07. Rs7203560 lies ~30 kb 
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upstream from hypersensitive site HS-33. The minor allele of this NPRL3 SNP shows a 
protective effect; as the number of minor alleles increases the hemolytic score decreases 
reflecting decreased hemolysis. These results were replicated in the Walk-PHaSST cohort 
(β=-0.52, pvalue=0.0143).  The results for the annotated SNPs are shown in Table 9.  
Genome-wide data was not available in the London cohort who consisted largely 
of African/West African/Afrocaribbean origin. In this validation cohort, rs7203560 was 
associated with lower hemolytic score (pvalue= 0.03674).  Rs7203560 was not as highly 
associated with the four hemolytic markers individually after adjusting for age and 
gender in the CSSCD cohort (Table 9).   
Four SNPs in olfactory receptor (OR) genes on chromosome chr11p; OR51I2 
(rs1391617: β= -0.17, pvalue=0.0003), OR51I1 (rs2445284: β= -0.42, pvalue=7.39x10-
05), OR51I1/OR51I2 rs7938426: β=-0.21, pvalue=6.08x10-05, rs7948471: β= -0.21, 
pvalue=5.87x10-05) were associated with the hemolytic score although below the 
generally accepted level for genome-wide significance. These results were replicated in 
the Walk-PHaSST and PUSH cohorts and rs794847 in OR51I1/OR51I2 was validated in 
the London cohort (Table 9).  When a meta-analysis of genome-wide data was done, 
rs7203560 and OR receptor polymorphisms all met genome-wide significance levels 
(Table 9). 
 Rs7203560, a SNP in the first intron of NPRL3 (Nitrogen Permease Regulator-
Like 3; C16orf35; chr 16p13.3) was most significantly associated with hemolytic score. 
NPRL3 is highly conserved and upstream of the human HBA1/HBA2 gene cluster in all 
vertebrates examined. 52  Its functions are unknown, although, its deletion causes 
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embryonic lethality from multiple cardiovascular defects 53. Within introns of NPRL3 lie 
the hemoglobin A, HBA1/HBA2 gene regulatory elements, HS-48, HS-40 and HS-33 that 
are required HBA1/HBA2 gene expression 52. SNPs very close to the α-globin regulatory 
elements are in strong linkage disequilibrium (LD) with rs7203560. 
When examining the association between these top SNPs and the other hemolytic 
components, we see that there is more power to detect these SNPs using the PCA to 
create a summary phenotype (Table 10).   
We show through an applied setting that using a summary phenotype computed 
through PCA has more power to detect SNPs associated with hemolysis instead of 
finding SNPs by examining the intersection of the top univariate GWAS results for each 
hemolytic trait.  We see that in Tables 8 and 9 there is more power to detect these SNPs 
with the summary phenotype.  We see in Table 10 that there are few SNPs that meet this 
significance threshold for all four univariate tests and there is no biological evidence to 
support the fact that the SNPs are associated with hemolysis. 
2.6 Discussion 
 We ran simulations and analyses comparing the methods of using the 1st PC as a 
summary phenotype to detect genetic variants that are associated with multiple traits that 
are used to define a phenotype and using the results of multiple univariate analyses.   
We show through simulation that the PCA approach has more power to detect 
SNPs that associated with correlated traits in comparison to identifying SNPs through 
univariate GWAS and examining the intersection of these analyses; however, there is 
also a higher type I error rate.   The probability of making a type I error with the 
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intersection method was much lower due to the fact that the SNP had to be associated 
with all 5 traits.  With the PCA approach, a SNP may by chance be moderately associated 
with only 1 to 2 traits; however the 1st PC may still show a strong association with that 
SNP.  There is a trade-off between power and false discovery rate between the two 
methods.  The optimal approach depends on the goal of the study. 
 The PCA approach provides several advantages in comparison to examining the 
intersection of the top results for each univariate GWAS.  To find genetic variants using 
the intersection method requires SNPs to be highly significant in all correlated traits.  
Oftentimes, we may only see highly significant results for only a few of the correlated 
traits.  One could circumvent this problem by lowering the type I error rate; however, this 
will increase the amount of false positives.  The PCA approach allows for a decrease in 
the type II error rate that will not increase the type I error rate. 
 Multivariate approaches are generally more efficient than multiple univariate 
approaches in the presence of correlated outcomes when outcomes depend on difference 
sets of independent variables and predictors.  In addition, traditional multivariate analyses 
can simplify the multiple comparisons issue that arises with multiple univariate analyses.  
Multiple trait analysis with genetic association data has a lot of promise in the context of 
systems biology to identify biological networks associated with disease.  The results of 
these analyses were published in Milton, Jacqueline N., et al. "A genome-wide 
association study of total bilirubin and cholelithiasis risk in sickle cell anemia." PloS 
one 7.4 (2012): e34741 and Milton, Jacqueline N., et al. "Genetic determinants of 
haemolysis in sickle cell anaemia." British journal of haematology (2013).  
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Table 1A Correlation Between Simulated Traits: Consistent Effects 
 Trait 1 Trait 2 Trait 3 Trait 4 Trait 5 
Trait 1  0.998 
>2e-16 
0.889 
>2e-16 
0.967 
>2e-16 
0.901 
>2e-16 
Trait 2   0.881 
>2e-16 
0.920 
>2e-16 
0.914 
>2e-16 
Trait 3    0.935 
>2e-16 
0.983 
>2e-16 
Trait 4     0.919 
>2e-16 
Trait 5      
This table provides information about pairwise Pearson correlation (top number) and the 
pvalue showing significance of the correlation (bottom number) in the simulation 
scenario where the effect sizes are in a consistent direction for the additive genetic 
models. 
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Table 1B Correlation Between Simulated Traits: Inconsistent Effects 
 Trait 1 Trait 2 Trait 3 Trait 4 Trait 5 
Trait 1  -0.998 
>2e-16 
-0.893 
>2e-16 
0.975 
>2e-16 
0.917 
>2e-16 
Trait 2   0.874 
>2e-16 
-0.969 
>2e-16 
-0.909 
>2e-16 
Trait 3    -0.919 
>2e-16 
-0.975 
>2e-16 
Trait 4     0.910 
>2e-16 
Trait 5      
This table provides information about pairwise Pearson correlation (top number) and the 
pvalue showing significance of the correlation (bottom number) in the simulation 
scenario where the effect sizes are not in a consistent direction for the additive genetic 
models. 
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Table 1C Correlation Between Simulated Traits: Null Trait 
 Trait 1 Trait 2 Trait 3 Trait 4 Trait 5 
Trait 1  -0.996 
>2e-16 
-0.901 
>2e-16 
0.975 
>2e-16 
.004 
0.8907 
Trait 2   0.862 
>2e-16 
-0.958 
>2e-16 
-0.002 
0.9393 
Trait 3    -0.897 
>2e-16 
-0.01 
0.7374 
Trait 4     -0.002 
0.9471 
Trait 5      
This table provides information about Pearson correlation (top number) and the pvalue 
showing significance of the correlation (bottom number) for the simulation scenario 
where there are four correlated traits and a fifth trait (the null trait) which is not correlated 
with the other four traits or the SNPs.  
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Table 2A Power of Multiple Trait Simulation Results 
Variability Pvalue 
Threshold 
Direction of 
Effects 
PC1 
Power 
PC1 
Type I 
Error* 
Intersection 
Power 
Intersection 
Type I Error* 
Low 5E-04 Consistent 0.998 5.13 0.984 3.18 
Inconsistent 0.998 7.35 0.983 5.91 
5E-06 Consistent 0.997 2.43 0.962 2.26 
Inconsistent 0.997 3.08 0.964 1.87 
5E-08 Consistent 0.997 0.36 0.775 0.002 
Inconsistent 0.997 0.73 0.787 0 
Medium 5E-04 Consistent 0.951 3.35 0.770 2.76 
Inconsistent 0.958 1.97 0.766 1.86 
5E-06 Consistent 0.842 1.26 0.715 0.96 
Inconsistent 0.830 0.87 0.709 0.68 
5E-08 Consistent 0.757 0.39 0.608 0 
Inconsistent 0.740 0 0.660 0 
High 5E-04 Consistent 0.780 0.98 0.369 0 
Inconsistent 0.774 0.002 0.387 0 
5E-06 Consistent 0.697 0 0.321 0 
Inconsistent 0.684 0.001 0.335 0 
5E-08 Consistent 0.583 0 0.289 0 
Inconsistent 0.551 0 0.295 0 
*The type I error rates are estimated per 1,000 
Simulation results for comparing the type I error and power for the PCA method and the 
intersection method when changing the variability of the phenotype, the pvalue threshold 
for significance and the direction of the effects. 
  
28 
 
 
Table 2B Power of Multiple Trait Simulation Results: Null Trait 
Variability Pvalue 
Threshold 
PC1 
Power 
PC1 
Type I 
Error* 
Low 5E-04 0.996 3.62 
5E-06 0.992 1.56 
5E-08 0.991 0 
Medium 5E-04 0.893 3.35 
5E-06 0.812 1.26 
5E-08 0.798 0 
High 5E-04 0.793 0.43 
5E-06 0.688 0 
5E-08 0.614 0 
*The type I error rates are estimated per 1,000 
Simulation results for the type I error and power for the PCA method when changing the 
variability of the phenotype, the pvalue threshold for significance and the direction of the 
effects. 
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Table 3 Multiple Trait Simulation Results with Environmental Variable 
Variability Pvalue 
Threshold 
Direction 
of Effects 
PC1 
Power 
PC1 
Type I 
Error* 
Intersection 
Power 
Intersection 
Type I Error* 
Low 5E-04 Consistent 0.951 4.68 0.935 3.77 
Different 0.946 2.94 0.921 2.19 
5E-06 Consistent 0.951 2.72 0.899 2.76 
Different 0.946 2.30 0.876 1.18 
5E-08 Consistent 0.950 0.18 0.775 0.005 
Different 0.944 0.93 0.787 0 
Medium 5E-04 Consistent 0.931 2.91 0.708 2.16 
Different 0.929 3.32 0.792 1.45 
5E-06 Consistent 0.842 2.58 0.686 0.76 
Different 0.767 1.27 0.591 0.54 
5E-08 Consistent 0.608 0.17 0.442 0 
Different 0.647 0 0.501 0 
High 5E-04 Consistent 0.695 0.69 0.351 0.002 
Different 0.672 0.001 0.308 0 
5E-06 Consistent 0.582 0 0.278 0 
Different 0.609 0.001 0.335 0 
5E-08 Consistent 0.514 0 0.198 0 
Different 0.478 0 0.215 0 
*The type I error rates are estimated per 1,000 
Simulation results for comparing the type I error and power for the PCA method and the 
intersection method when changing the variability of the phenotype, the pvalue threshold 
for significance and the direction of the effects when including an environmental variable 
that is also associated with phenotype. 
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Table 4A Patient Characteristics for Participants in Serum Bilirubin GWAS 
 
 CSSCD 
Clinical Variable Overall (N=1117) Men (N=533) Women (N=584) 
Log Total Bilirubin 
(mg/dL)* 1.13(0.5) 1.19(0.5) 1.13(0.5) 
Reticulocyte (%) 12.09(5.9) 11.79(5.6) 12.09(5.9) 
AST  (units/dL) 50.52(32.2) 48.68(34.5) 50.52(32.2) 
ALT (units/dL) 22.14(22.6) 22.25(24.7) 22.14(22.6) 
Hemoglobin (g/dL) 8.43(8.5) 8.49(1.3) 8.43(8.5) 
LDH (mg/dL) 421.1(91.1) 438.1(88.4) 421.1(91.1) 
Age (years) 16.41(11.5) 15.29(11.1) 16.41(11.5) 
 
Summary statistics of patient characteristics in the CSSCD study.  For each study, the 
first column reports statistics (mean and standard deviation) for all patients included in 
the analysis and the second and third column report statistics stratified by gender. 
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Table 4B Patient Characteristics for Participants in Serum Bilirubin GWAS 
 
 MSH 
Clinic Variable Overall (N=195) Men (N=96) Women (N=99) 
Log Total Bilirubin 
(mg/dL) 1.09(0.6) 1.15(0.6) 1.04(0.6) 
Reticulocyte (%) 15.06(8.1) 14.13(7.8) 15.90(8.3) 
AST  (units/dL) 41.45(19.3) 42.03(19.1) 40.91(19.6) 
ALT (units/dL) 24.14(15.8) 24.81(15.6) 23.52(16.1) 
Hemoglobin (g/dL) 8.56(1.4) 9.01(1.4) 8.14(1.3) 
LDH (mg/dL) 421.1(91.1) 438.1(88.4) 421.1(91.1) 
Age (years) 16.41(11.5) 15.29(11.1) 16.41(11.5) 
 
Summary statistics of patient characteristics in the MSH study.  For each study, the first 
column reports statistics (mean and standard deviation) for all patients included in the 
analysis and the second and third column report statistics stratified by gender. 
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Table 4C Patient Characteristics for Participants in Serum Bilirubin GWAS 
 Walk-PHaSST 
Clinical Variable Overall (N=522) 
Men 
(N=241) 
Women 
(N=281) 
Log Total Bilirubin 
(mg/dL)* 3.67(0.7) 3.81(0.7) 3.55(0.7) 
Reticulocyte (%) 8.61(5.5) 8.99(5.6) 8.28(5.5) 
AST  (units/dL) 46.27(34.9) 51.55(41.4) 41.77(27.4) 
ALT (units/dL) 28.33(22.4) 30.23(23.3) 26.61(21.5) 
Hemoglobin (g/dL) 9.37(2.0) 9.63(2.1) 9.14(1.8) 
LDH (mg/dL) 454.43(292.6) 493.05(316.4) NA 
Age (years) 36.69(13.2) 34.87(13.1) 8.96(2.4) 
 
*Walk-PHaSST bilirubin measurement is in SI units 
Summary statistics of patient characteristics in the Walk-PHaSST study.  For each study, 
the first column reports statistics (mean and standard deviation) for all patients included 
in the analysis and the second and third column report statistics stratified by gender. 
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Table 4D Patient Characteristics for Participants in Serum Bilirubin GWAS 
 
 
Summary statistics of patient characteristics in the Duke study.  For each study, the first 
column reports statistics (mean and standard deviation) for all patients included in the 
analysis and the second and third column report statistics stratified by gender. 
  
 Duke 
Clinical 
Variable 
Overall 
(N=530) 
Men 
(N=242) 
Women 
(N=288) 
Log Total 
Bilirubin 
(mg/dL) 
0.83 (0.7) 0.89 (0.8) 0.78 (0.7) 
Reticulocyte 
(%) 10.35 (6.0) 10.22 (6.0) 10.45 (6.1) 
AST  
(units/dL) 46.56 (34.6) 47.69 (29.2) 45.61 (38.5) 
ALT 
(units/dL) 30.93 (28.2) 32.41 (28.7) 29.69 (27.8) 
Hemoglobin 
(g/dL) 8.75 (1.8) 9.20 (2.1) 8.40 (1.6) 
LDH 
(mg/dL) NA NA NA 
Age (years) 33.67 (11.9) 32.34 (11.0) 34.79 (12.6) 
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Table 5 Correlation between Hemolytic Markers 
Variables LDH AST Reticulocyte Serum Bilirubin 
LDH  0.42 
<2.2e-16 
0.20 
2.75e-11 
0.22 
1.81e-13 
AST   0.07 
0.017 
0.09 
0.001 
Reticulocyte     0.42 
<2.2e-16 
Serum Bilirubin     
Here we show the results of the correlation between the hemolytic markers.  The top 
number is the correlation and the bottom number is the pvalue. 
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Figure 1 Manhattan Plot Serum Bilirubin GWAS 
 
Here we show the Manhattan plot of the GWAs results for SNPs with a MAF greater than 
.05.  On the x axis is the chromosome position and on the y axis is the –log10(pvalue).  
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Figure 2 QQ Plot for Serum Bilirubin GWAS 
 
The QQ plot of the GWAS results for serum bilirubin shows the expected –log10(pvalue) 
on the x axis and the observed –log10(pvalue) on the y axis. 
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Table 6A SNPs Associated with Serum Bilirubin 
Variant Information CSSCD 
SNP Chr BP 
Coded 
Allele 
 
MAF Genes β pvalue 
rs7586110 2 234255266 C  0.26 
UGT1A6-
UGT1A10 0.11 2.63E-08 
rs10168155  2 234261575 
A 
 0.37 
UGT1A6-
UGT1A10 0.11 5.72E-09 
rs10168416  2 234261826 
G 
 0.24 
UGT1A6-
UGT1A10 0.12 5.55E-09 
rs6759892 2 234266408 C  0.38 
UGT1A6-
UGT1A10 0.10 7.71E-09 
rs1105880 2 234266704 G  0.36 
UGT1A6-
UGT1A10 0.11 1.20E-09 
rs2070959 2 234266930 G  0.25 
DNAJB3,  
UGT1A3-
UGT1A10 
0.13 4.05E-10 
rs1105879 2 234266941 C  0.30 
UGT1A6-
UGT1A10 0.13 1.39E-11 
rs17863787 2 234275833 C  0.25 
UGT1A6-
UGT1A10 0.14 3.34E-11 
rs3755319  2 234332321 
A 
 0.29 
UGT1A1-
UGT1A10  -0.14 1.82E-12 
rs887829  2 234333309 
A 
 0.45 
UGT1A1-
UGT1A10  0.19 5.27E-25 
rs6742078  2 234337378 
A 
 0.43 
UGT1A1-
UGT1A10  0.18 1.71E-23 
rs4148324  2 234337461 
C 
 0.45 
UGT1A1-
UGT1A10  0.16 1.56E-19 
rs3771341  2 234337978 
A 
 0.40 
UGT1A1-
UGT1A10  0.17 4.17E-20 
rs4148325  2 234338048 
A 
 0.45 
UGT1A1-
UGT1A10  0.18 1.66E-24 
rs4148326  2 234338201 
A 
 0.39 
UGT1A1-
UGT1A10  -0.13 6.57E-13 
Genome-wide significant SNPs in the CSSCD discovery cohortThis table reports the 
SNP identifier, chromosome, physical coordinate, the coded allele in PLINK (also the 
minor allele), the MAF, the gene cluster where the SNP is located, the regression 
coefficient and pvalue. 
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Table 6B SNPs Associated with Serum Bilirubin 
Variant Information MSH 
SNP Chr BP Coded Allele  MAF Genes β pvalue 
rs7586110 2 234255266 C  0.26 
UGT1A6-
UGT1A10 0.07 .03347 
rs10168155  2 234261575 
A 
 0.37 
UGT1A6-
UGT1A10 
 
NA 
 
NA 
rs10168416  2 234261826 
G 
 0.24 
UGT1A6-
UGT1A10 
 
NA 
 
NA 
rs6759892 2 234266408 C  0.38 
UGT1A6-
UGT1A10 0.08 .0045 
rs1105880 2 234266704 G  0.36 
UGT1A6-
UGT1A10 NA NA 
rs2070959 2 234266930 G  0.25 
DNAJB3,  
UGT1A3-
UGT1A10 
 
0.07 
 
.05408 
rs1105879 2 234266941 C  0.30 
UGT1A6-
UGT1A10 0.07 .02737 
rs17863787 2 234275833 C  0.25 
UGT1A6-
UGT1A10 NA NA 
rs3755319  2 234332321 
A 
 0.29 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs887829  2 234333309 
A 
 0.45 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs6742078  2 234337378 
A 
 0.43 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs4148324  2 234337461 
C 
 0.45 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs3771341  2 234337978 
A 
 0.40 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs4148325  2 234338048 
A 
 0.45 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
rs4148326  2 234338201 
A 
 0.39 
UGT1A1-
UGT1A10  
 
NA 
 
NA 
Genome-wide significant SNPs in the CSSCD study and their replication results in the 
MSH cohort.  This table reports the SNP identifier, chromosome, physical coordinate, the 
coded allele in PLINK (also the minor allele), the MAF, the gene cluster where the SNP 
is located, the regression coefficient and pvalue in this particular study. 
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Table 6C SNPs Associated with Serum Bilirubin 
Variant Information Walk-PHaSST 
SNP Chr BP Coded Allele  MAF Genes β pvalue 
rs7586110 2 234255266 C  0.26 
UGT1A6-
UGT1A10 .20 .000107 
rs10168155  2 234261575 
A 
 0.37 
UGT1A6-
UGT1A10 0.18 0.000164 
rs10168416  2 234261826 
G 
 0.24 
UGT1A6-
UGT1A10 0.21 4.46E-05 
rs6759892 2 234266408 C  0.38 
UGT1A6-
UGT1A10 0.18 .000112 
rs1105880 2 234266704 G  0.36 
UGT1A6-
UGT1A10 0.18 0.000121 
rs2070959 2 234266930 G  0.25 
DNAJB3,  
UGT1A3-
UGT1A10 
0.21 5.56E-05 
rs1105879 2 234266941 C  0.30 
UGT1A6-
UGT1A10 0.18 .000189 
rs17863787 2 234275833 C  0.25 
UGT1A6-
UGT1A10 0.28 1.22E-08 
rs3755319  2 234332321 
A 
 0.29 
UGT1A1-
UGT1A10  
 
-0.26 
 
5.59E-08 
rs887829  2 234333309 
A 
 0.45 
UGT1A1-
UGT1A10  
 
0.37 
 
1.56E-18 
rs6742078  2 234337378 
A 
 0.43 
UGT1A1-
UGT1A10  
 
0.36 
 
3.67E-17 
rs4148324  2 234337461 
C 
 0.45 
UGT1A1-
UGT1A10  
 
0.35 
 
4.89E-16 
rs3771341  2 234337978 
A 
 0.40 
UGT1A1-
UGT1A10  
 
0.35 
 
1.53E-15 
rs4148325  2 234338048 
A 
 0.45 
UGT1A1-
UGT1A10  
 
0.37 
 
2.13E-18 
rs4148326  2 234338201 
A 
 0.39 
UGT1A1-
UGT1A10  
 
-0.28 
 
7.17E-11 
 
Genome-wide significant SNPs in the CSSCD study and their replication results in the 
Walk-PHaSST cohort.  This table reports the SNP identifier, chromosome, physical 
coordinate, the coded allele in PLINK (also the minor allele), the MAF, the gene cluster 
where the SNP is located, the regression coefficient and pvalue in this particular study. 
40 
 
 
Table 6D SNPs Associated with Serum Bilirubin 
Variant Information Duke 
SNP Chr BP 
Coded 
Allele 
 
MAF Genes β pvalue 
rs7586110 2 234255266 C  0.26 
UGT1A6-
UGT1A10 0.21 2.20E-05 
rs10168155  2 234261575 
A 
 0.37 
UGT1A6-
UGT1A10 
 
0.26 
 
4.44E-09 
rs10168416  2 234261826 
G 
 0.24 
UGT1A6-
UGT1A10 
 
0.21 
 
4.03E-05 
rs6759892 2 234266408 C  0.38 
UGT1A6-
UGT1A10 0.26 4.44E-09 
rs1105880 2 234266704 G  0.36 
UGT1A6-
UGT1A10 0.27 1.84E-09 
rs2070959 2 234266930 G  0.25 
DNAJB3,  
UGT1A3-
UGT1A10 
 
0.22 1.62E-05 
rs1105879 2 234266941 C  0.30 
UGT1A6-
UGT1A10 0.24 1.10E-06 
rs17863787 2 234275833 C  0.25 
UGT1A6-
UGT1A10 0.22 8.75E-06 
rs3755319  2 234332321 
A 
 0.29 
UGT1A1-
UGT1A10  
 
-0.29 
 
5.07E-09 
rs887829  2 234333309 
A 
 0.45 
UGT1A1-
UGT1A10  0.33 2.30E-14 
rs6742078  2 234337378 
A 
 0.43 
UGT1A1-
UGT1A10  0.33 3.18E-14 
rs4148324  2 234337461 
C 
 0.45 
UGT1A1-
UGT1A10  
 
0.33 
 
4.58E-14 
rs3771341  2 234337978 
A 
 0.40 
UGT1A1-
UGT1A10  
 
0.28 
 
2.08E-10 
rs4148325  2 234338048 
A 
 0.45 
UGT1A1-
UGT1A10  0.33 2.36E-14 
rs4148326  2 234338201 
A 
 0.39 
UGT1A1-
UGT1A10  
 
-0.27 
 
3.80E-09 
Genome-wide significant SNPs in the CSSCD study and their replication results 
in the Duke cohort.  This table reports the SNP identifier, chromosome, physical 
coordinate, the coded allele in PLINK (also the minor allele), the MAF, the gene cluster 
where the SNP is located, the regression coefficient and pvalue in this particular study. 
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Table 6E SNPs Associated with Serum Bilirubin 
Variant Information SITT 
SNP Chr BP Coded Allele  MAF Genes β pvalue 
rs7586110 2 234255266 C  0.26 
UGT1A6-
UGT1A10 0.24 8.65E-14 
rs10168155  2 234261575 
A 
 0.37 
UGT1A6-
UGT1A10 
 
0.24 
 
3.52E-16 
rs10168416  2 234261826 
G 
 0.24 
UGT1A6-
UGT1A10 
 
0.26 
 
1.16E-13 
rs6759892 2 234266408 C  0.38 
UGT1A6-
UGT1A10 0.24 7.31E-17 
rs1105880 2 234266704 G  0.36 
UGT1A6-
UGT1A10 0.26 3.13E-18 
rs2070959 2 234266930 G  0.25 
DNAJB3,  
UGT1A3-
UGT1A10 
 
0.26 
 
1.24E-15 
rs1105879 2 234266941 C  0.30 
UGT1A6-
UGT1A10 0.28 7.68E-20 
rs17863787 2 234275833 C  0.25 
UGT1A6-
UGT1A10 0.28 4.93E-18 
rs3755319  2 234332321 
A 
 0.29 
UGT1A1-
UGT1A10  
 
-0.28 
 
2.21E-18 
rs887829  2 234333309 
A 
 0.45 
UGT1A1-
UGT1A10  
 
0.41 
 
3.16E-46 
rs6742078  2 234337378 
A 
 0.43 
UGT1A1-
UGT1A10  
 
0.38 
 
1.43E-43 
rs4148324  2 234337461 
C 
 0.45 
UGT1A1-
UGT1A10  
 
0.37 
 
2.55E-38 
rs3771341  2 234337978 
A 
 0.40 
UGT1A1-
UGT1A10  
 
0.39 
 
1.26E-37 
rs4148325  2 234338048 
A 
 0.45 
UGT1A1-
UGT1A10  
 
0.40 
 
2.11E-47 
rs4148326  2 234338201 
A 
 0.39 
UGT1A1-
UGT1A10  
 
-0.31 
 
5.44E-26 
 
Genome-wide significant SNPs in the CSSCD study and their replication results in the 
SITT cohort.  This table reports the SNP identifier, chromosome, physical coordinate, the 
coded allele in PLINK (also the minor allele), the MAF, the gene cluster where the SNP 
is located, the regression coefficient and pvalue in this particular study.  
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Table 7 Association with LDH, Reticulocytes and AST 
 LDH Reticulocytes AST 
SNP β pval β pval β pval 
rs7586110 -0.01206 0.235 0.01255 0.4964 0.003 0.8093 
rs10168155 -0.00587 0.5304 -0.0032 0.8501 -0.003 0.7496 
rs10168416 -0.0042 0.6886 0.01099 0.563 0.003 0.7967 
rs6759892 -0.00604 0.5171 0.001128 0.9466 -0.005 0.6304 
rs1105880 0.000316 0.9729 7.16E-05 0.9966 -0.003 0.7901 
rs2070959 -0.00319 0.7579 0.01636 0.3834 0.006 0.627 
rs1105879 -0.00135 0.8891 0.02488 0.1554 0.005 0.6752 
rs17863787 0.00116 0.9146 0.006013 0.7586 0.0009 0.9446 
rs3755319 -0.00043 0.9653 0.006524 0.7188 -0.009 0.4779 
rs887829 -0.00528 0.558 -0.01726 0.2922 -0.001 0.9145 
rs6742078 -0.00786 0.3855 -0.01868 0.2558 0.005 0.626 
rs4148324 -0.00463 0.6104 -0.02468 0.1339 0.007 0.5794 
rs3771341 -0.00911 0.3252 -0.01876 0.2654 0.008 0.4962 
rs4148325 -0.00799 0.3732 -0.02165 0.1877 -0.003 0.7825 
rs4148326 0.003204 0.7309 0.01245 0.462 -0.011 0.3565 
This table reports the association of the genome-wide significant SNPs and their 
association with the other hemolytic markers. 
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Table 8A Characteristics of Patients in Hemolysis GWAS 
 CSSCD (n=1,117) 
Variable Overall M(n=585) F(n=532) 
Age  17.86(11.71) 18.85(11.98) 16.79(11.31) 
Hemoglobin  2.11(0.14) 2.10(0.13) 2.12(0.15) 
Hematocrit 3.18(0.15) 3.17(0.14) 3.18(0.17) 
HbF 1.80(0.52) 1.86(0.51) 1.73(0.52) ∝ thalassemia 370(33.3%) 189(32.3%) 181(34%) 
AST 3.74(0.29) 3.81(0.27) 3.67(0.20) 
LDH 6.02(0.22) 5.98(0.21) 6.06(0.23) 
Reticulocyte 2.36(0.40) 2.37(0.39) 2.35(0.40) 
Bilirubin 1.13(0.51) 1.19(0.51) 1.08(0.51) 
Hemolytic 
Score 
-2.97x10-18(1.08) 0.20(1.53) -0.22(1.49) 
 
Summary statistics of patient characteristics in the CSSCD discovery cohort.  For each 
cohort, the first column reports statistics (mean and standard deviate or frequencies) for 
all patients included in the analysis and the second and third columns report statistics 
stratified by gender.  AST, LDH, reticulocyte, bilirubin, hemoglobin, HbF and hematocrit 
are reported clinic adjusted values for the CSSCD cohort.  
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Table 8B Characteristics of Patients in Hemolysis GWAS 
 Walk-PHaSST(n=449) 
Variable Overall M(n=207) F(n=242) 
Age  37.20(13.20) 35.81(12.94) 38.35(13.34) 
Hemoglobin  2.24(0.69) 2.26(0.80) 2.23(0.55) 
Hematocrit 3.08(2.51) 3.12(2.54) 3.01(2.51) 
HbF 1.64(1.48) 1.57(1.49) 1.69(1.46) ∝ thalassemia 129(30.1%) 56(28.4%) 73(31.6%) 
AST 3.80(1.35) 3.91(0.53) 3.70(0.50) 
LDH 6.08(0.59) 6.00(0.59) 6.16(0.96) 
Reticulocyte 2.11(0.73) 2.15(0.73) 2.08(0.73) 
Bilirubin 2.48(1.35) 2.67(1.38) 2.35(1.32) 
Hemolytic 
Score* 
-2.18x10-16(1.00) 0.29(1.59) -0.23(1.51) 
Summary statistics of patient characteristics in the Walk-PHaSST cohort.  For each 
cohort, the first column reports statistics (mean and standard deviate or frequencies) for 
all patients included in the analysis and the second and third columns report statistics 
stratified by gender.  AST, LDH, reticulocyte, bilirubin, hemoglobin and hematocrit are 
reported as log transformed values in the Walk-PHaSST cohort.  M-male, F-female. HbF 
values are reported as cubic root transformed values in the Walk-PHaSST cohort. *Walk-
PHaSST variables measured in SI units.  
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Table 8C Characteristics of Patients in Hemolysis GWAS 
 PUSH (n=296) 
Variable Overall M(n=140) F(n=156) 
Age  11.85(5.42) 12.04(5.25) 11.65(5.61) 
Hemoglobin  2.22(0.57) 2.23(0.69) 2.22(0.39) 
Hematocrit 3.28(1.69) 3.28(1.81) 3.28(1.52) 
HbF 2.20(1.98) 2.09(1.96) 2.32(1.97) ∝ thalassemia 38 (32.2%) 51 (43.22%) 29 (24.58%) 
AST 3.85(0.40) 3.89(0.40) 3.81(0.39) 
LDH 6.17(0.48) 6.17(0.43) 6.17(0.53) 
Reticulocyte 2.17(0.73) 2.17(0.80) 2.17(0.67) 
Bilirubin 0.99(0.65) 1.08(0.70) 0.91(0.58) 
Hemolytic 
Score -7.17x10
-16(1.08) 0.21(1.62) -0.22(1.50) 
Summary statistics of patient characteristics in the PUSH cohort.  For each cohort, the 
first column reports statistics (mean and standard deviate or frequencies) for all patients 
included in the analysis and the second and third columns report statistics stratified by 
gender.  AST, LDH, reticulocyte, bilirubin, hemoglobin and hematocrit are reported as 
log transformed values in the PUSH cohort.  M-male, F-female. HbF values are reported 
as cubic root transformed values in the PUSH cohort. 
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Table 8D Characteristics of Patients in Hemolysis GWAS 
 London (n=213) 
Variable Overall M(n=94) F(n=119) 
Age  33.02(10.89) 32.30(10.55) 33.59(11.17) 
Hemoglobin  2.11(0.18) 2.17(0.18) 2.08(0.16) 
Hematocrit NA NA NA 
HbF 1.79(0.48) 1.67(0.47) 1.89(0.46) ∝ thalassemia 75(35%) 28(30%) 47(39%) 
AST 3.71(0.32) 3.78(0.33) 3.66(0.31) 
LDH 6.04(0.32) 6.04(0.35) 6.04(0.31) 
Reticulocyte 5.81(0.43) 5.89(0.32) 5.74(0.48) 
Bilirubin 3.86(0.56) 4.00(0.58) 3.75(0.52) 
Hemolytic 
Score 1.82x10
-16(1.06) 0.29(1.37) -0.23(1.32) 
Summary statistics of patient characteristics in the London validation cohort.  For each 
cohort, the first column reports statistics (mean and standard deviate or frequencies) for 
all patients included in the analysis and the second and third columns report statistics 
stratified by gender. M-male, F-female. HbF values are reported as cubic root 
transformed values. 
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Figure 3Hemolytic Score Associated with Hemolytic Components 
 
Here we show the scatterplots of the hemolytic score with each of the hemolytic traits.  
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Figure 4 Manhattan Plot of Hemolysis GWAS 
 
Here we show the Manhattan plot of the hemolytic score (1st principal component) 
GWAS.  On the x axis is the chromosome position for each SNP and on the y axis is the 
–log10(pvalue). 
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Figure 5 QQ Plot of Hemolysis GWAS 
 
The QQ plot from the GWAS using the 1st principal component (hemolytic) as the 
phenotype.  
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Table 9A SNPs Associated with Hemolytic Score 
 
Variant Information CSSCD 
SNP Chr Gene bp Coded 
Allele 
 
β SE pvalue 
rs7203560 16 NPRL3 184390 C -0.44 0.09 6.04x10-07 
rs7948471 11 OR51I2,OR51I1 5471746 A -0.21 0.05 5.87x10-05 
rs7938426 11 OR51I2,OR51I1 5471832 G -0.21 0.05 6.08x10-05 
rs2445284 11 OR51L1 5029703 G -0.42 0.10 7.39x10-05 
 
SNPs meeting significance threshold (5x10-04) in the CSSCD study that replicate in the 
three independent cohorts. The table reports the SNP identifier from dbSNP, 
chromosome, physical coordinates (human genome [hg]19), the coded allele in PLINK 
(also minor allele), the gene clusters where the SNP is located, and regression coefficient, 
standard error and p-value. Additive models of association were used in all studies 
adjusting for age and gender.  
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Table 9B SNPs Associated with Hemolytic Score 
Variant Information Walk-PHaSST 
SNP Chr Gene bp Coded 
Allele 
 
β SE pvalue 
rs7203560 16 NPRL3 184390 C -0.53 0.22 0.014 
rs7948471 11 OR51I2,OR51I1 5471746 A -0.35 0.11 0.002 
rs7938426 11 OR51I2,OR51I1 5471832 G -0.37 0.11 0.0012 
rs2445284 11 OR51L1 5029703 G -1.32 0.15 1.60x10-17 
 
SNPs meeting significance threshold (5x10-04) in the CSSCD study that replicate in the 
three independent cohorts. The table reports the SNP identifier from dbSNP, 
chromosome, physical coordinates (human genome [hg]19), the coded allele in PLINK 
(also minor allele), the gene clusters where the SNP is located, and regression coefficient, 
standard error and p-value. Additive models of association were used in all studies 
adjusting for age and gender.  
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Table 9C SNPs Associated with Hemolytic Score 
Variant Information PUSH 
SNP Chr Gene bp Coded 
Allele 
 
β SE pvalue 
rs7203560 16 NPRL3 184390 C -0.13 0.31 0.672 
rs7948471 11 OR51I2,OR51I1 5471746 A -0.39 0.14 0.004 
rs7938426 11 OR51I2,OR51I1 5471832 G -0.39 0.14 0.004 
rs2445284 11 OR51L1 5029703 G -1.75 0.17 3.01x10-21 
 
SNPs meeting significance threshold (5x10-04) in the CSSCD study that replicate in the 
three independent cohorts. The table reports the SNP identifier from dbSNP, 
chromosome, physical coordinates (human genome [hg]19), the coded allele in PLINK 
(also minor allele), the gene clusters where the SNP is located, and regression coefficient, 
standard error and p-value. Additive models of association were used in all studies 
adjusting for age and gender.  
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Table 9D SNPs Associated with Hemolytic Score 
Variant Information London 
SNP Chr Gene bp Coded 
Allele 
 
β SE pvalue 
rs7203560 16 NPRL3 184390 C -0.42 0.20 0.0367 
rs7948471 11 OR51I2,OR51I1 5471746 A -0.46 0.15 0.017 
rs7938426 11 OR51I2,OR51I1 5471832 G NA NA NA 
rs2445284 11 OR51L1 5029703 G 0.41 0.28 0.146 
 
SNPs meeting significance threshold (5x10-04) in the CSSCD study that replicate in the 
three independent cohorts. The table reports the SNP identifier from dbSNP, 
chromosome, physical coordinates (human genome [hg]19), the coded allele in PLINK 
(also minor allele), the gene clusters where the SNP is located, and regression coefficient, 
standard error and p-value. Additive models of association were used in all studies 
adjusting for age and gender.  
  
54 
 
 
Table 10 Association between SNPs and other Hemolytic Components 
SNP Chr Reticulocyte  LDH AST Bilirubin 
Gene β pvalue β pvalue β pvalue β pvalue 
rs7203560 
16 -0.15 5.1x10-06 -0.07 2x10-04 -0.07 0.003 -0.10 0.028 
NPRL3 
rs7948471 
11 
 
-0.04 0.064 -0.02 0.056 -0.05 6x10-04 -0.08 2x10-04 
OR51I2 
OR51I1 
rs7938426 
11 
 
-0.04 0.068 -0.02 0.055 -0.05 4x10-04 -0.08 3x10-04 
OR51I2 
OR51I1 
rs2445284 
11 
 
-0.20 8.1x10-07 -0.07 0.001 0.004 0.8653 -0.10 0.0010 
OR51L1 
The table reports the association between the SNPs that were found to be associated with 
the hemolytic score in CSSCD and the validation cohorts and their association with the 
four hemolytic components (β is the regression coefficient). 
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3 Evaluation of Ensemble Genetic Risk Scores in Phenotype Prediction 
3.1 Introduction 
 
GWAS have identified genetic variants that are highly associated with a variety of 
diseases/disease phenotypes.  One of the drawbacks to a GWAS is that the most 
significant SNPs often have small to modest effect sizes and only explain a small 
proportion of the variability of the disease phenotype. Combining genetic markers into a 
genetic risk score (GRS) is an approach to help explain a larger amount of the variability 
of a phenotype. The challenge of this approach is to select the optimal number of 
markers. To overcome this challenge, in this chapter we propose creating an ensemble of 
genetic risk models with GRS composed by different numbers of SNPs to produce more 
stable predictions and use this approach to develop a robust genetic risk model. 
In section 3.3 we introduce this novel method of predicting a continuous trait 
through creating an ensemble of genetic risk models and compare it to the tradition GRS 
approach and with 10 fold CV.  This method extends the approach introduced in 
Sebastiani et al. 201218 for building genetic risk prediction models from case control 
studies to predict quantitative traits. In section 3.4 we apply this novel approach to predict 
HbF in SCA patients by using the results of a previously published GWAS54.  We show 
through simulation that an ensemble of GRS models yields a similar peak in variability of 
the phenotype explained; however, the ensemble of GRS models is more robust to the 
inclusion of false positives and creates more stable predictions.  We show through an 
applied setting that as a result of the ensemble of GRS models’ robustness that even if we 
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choose an incorrect number of genetic variants to include in the final model, we do not 
lose a substantial amount of explained variability. 
 
3.2 Methods 
3.2.1 Development of GRS 
The results of a GWAS or a list of genetic variants are ordered by decreasing 
significance.  The unweighted GRS are then computed by cumulatively adding the 
number of risk alleles as follows: 
𝐺𝑅𝑆!,! =    𝑅𝑖𝑠𝑘  𝐴𝑙𝑙𝑒𝑙𝑒!,!!!!!  
where Risk Allelei,j is the number of risk alleles for the jth SNP for individual i.  We also 
computed a weighted GRS: 
𝐺𝑅𝑆!,! =    𝑅𝑖𝑠𝑘  𝐴𝑙𝑙𝑒𝑙𝑒!,! ∗!!!! 𝑡! 
where tj is the t statistic computed from the GWAS for the association between the 
phenotype and SNP j.  We then take the N GRS and use them as covariates to compute N 
linear regression models as follows: 𝑦!,! =   𝛽!,! +   𝛽!,!𝐺𝑅𝑆!,! 
 
where yi is the phenotype for individual i.  The N GRS models are then evaluated by 
taking an independent validation cohort to compute N GRS and computing 𝑦! for each of 
the N GRS models.  Using the same study to evaluate the GRS that was used to generate 
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the score will result in overfitting the model and consequently yield over optimistic 
results (high correlation between the predicted and observed phenotype).  To assess 
prediction accuracy the correlation between the observed and predicted phenotype is 
computed in the validation cohort(s). 
3.2.2 Development of Ensemble of GRS Models 
Phenotype prediction can also be accomplished by using an ensemble of GRS 18.  
The idea of ensemble methodology is to build a predictive model by averaging the 
predicted values over multiple models.  Using an ensemble of GRS the predicted value of 
a phenotype is computed by taking the cumulative average over multiple GRS as follows: 
𝑦!,! =    1𝑁 𝑦!,!!!!!  
where N is the number of genetic variants in the GRS model for individual i for the jth 
genetic variant.  The prediction accuracy is assessed by computing the correlation 
between the observed and predicted phenotype.   
3.2.3 10 Fold Cross Validation 
A 10-fold cross validation method was employed to compare the results of 
phenotype prediction 55.  The dataset was randomly partitioned into 10 equal datasets.   
Nine of the 10 datasets are compiled as the training dataset and then used for GRS model 
development and the 10th dataset is the test dataset which is used for model evaluation by 
computing the correlation between the observed and predicted values.  The process is 
repeated until all of the 10 partitions are used as the test dataset.  The prediction results 
from the 10 different model evaluations are then averaged. 
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3.2.4 Simulation Design 
We tested the prediction accuracy of the GRS, ensemble GRS and 10-fold CV 
prediction methods on simulated data.  The following steps describe how the simulation 
model works 56: 
Step 1: Generate the allele frequency for each genetic variant 
The minor allele frequency was generated assuming a uniform (.05,0.50) distribution for 
j=1,000 bialleleic single nucleotide polymorphisms (SNPs).  The 0.05, 0.50 cutoffs of the 
uniform distribution are used to consider only common variants. 
Step 2: Generate the genotypes. 
The genotypes are generated for a sample of 1,000 individuals based on the assumption 
of Hardy-Weinberg equilibrium (aa, aA, or AA) for each SNP. 
Step 3: Generate the phenotype 
The phenotype is generated from a linear regression model with m = 5,10 and 30 causal 
SNPs (out of j=1,000) with a random error incorporated that is equal to a quarter of the 
mean (low variability), half the mean (medium variability) and the three quarters of the 
mean (high variability) to vary the variability of the linear regression model.  Each causal 
SNP contributes an equal genetic effect to the phenotype based on an additive genetic 
model with three different levels of heritability, low (h2 = 0.20), medium (h2=0.40) and 
high (h2=0.60).   
Locus-specific heritability, the amount of heritability contributed by the mth causal SNP 
was computed as: ℎ!!  = !!!  
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where m is the number of causal SNPs.  This implies that all causal SNPs contribute to 
the total heritability by an equal amount. 
Effect size a for each causal SNP is computed from the formula: 
ℎ!! =    𝜎!!𝜎!"#$%! =    2𝑝 1− 𝑝 𝑎𝜎!"#$%!  
where 𝜎!"#$%!   is the total phenotypic variability, and a is the additive genetic effect.  In 
our simulations, for each heritability (low, medium and high) we vary the variability (1/4, 
½ and ¾ the mean of the phenotype).  For each causal SNP, we randomly draw from 𝑅!,!  ~  𝑁 𝑎!𝐺!,!, !!"#$%!!   where  𝑎! is the effect of mth causal SNP and 𝐺!,!  is the 
additive genotype coding for ith individual at mth causal SNP.  The phenotype is then 
computed as follows: 
𝑦! =    𝑅!,!!!!!  
 
Step 4: Randomly separate the data into a training and test dataset. 
The 1,000 individuals are randomly separated into 900 individuals for a training dataset 
and 100 individuals for a test dataset. 
Step 5: Generate GRS models for the training dataset 
A single SNP analysis was performed for all of the SNPs and the SNPs were then sorted 
by order of significance and then computed a GRS for the 900 individuals in the training 
dataset for all 1,000 SNPs.  We then used these GRS models to generate linear regression 
models with the GRS as a covariate. 
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Step 6: Compute GRS for the test dataset 
Compute the GRS for the test dataset based on the order of significance from the single 
SNP analysis for the training dataset. 
Step 7: Compute predicted phenotype values for the test dataset 
Based on the 1,000 GRS models estimated from the training dataset predict the 
phenotype for the test dataset. 
Step 8: Compute the predicted value for the ensemble GRS models. 
Step 9: Run a 10 fold CV and compute the predicted values as an average over the 10 
folds. 
Step 10: Compute the correlation between the observed and predicted phenotype for the 
three methods. 
3.3 Simulation Results 
In our simulations we monitored the correlation between the observed and predicted 
phenotype for each GRS model for all 1,000 simulations.  In Figures 6 through 8 we 
show the boxplots of the correlation between the predicted and observed values for the 
GRS, ensemble GRS models.  We see that for both the GRS and ensemble GRS methods 
that the correlation peaks at 5 SNPs; however, after 5 SNPs the correlation rapidly 
decreases for the GRS method while the decrease in correlation is more gradual for the 
ensemble GRS method.  Therefore, if one were to incorrectly choose the wrong model, 
the loss in prediction accuracy would be less when using the ensemble GRS method in 
comparison to using the GRS method.  In Figures 6 through 8 we also show bar plots of 
the number of SNPs in the most predictive model for the CV method in which we 
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simulated 5 causal SNPs with low, medium and high heritability; respectively.  We see 
that in the models in which there is low variability in the phenotype the most accurate 
model is always the correct model; however, as the variability in the phenotype increases 
the accuracy of choosing the correct model decreases although the majority of the time 
the most predictive model is the correct model.  In Figures 9 through 11 we show the 
boxplots of the correlation between the predicted and observed values for the GRS and 
ensemble GRS prediction methods in which we simulated 10 causal SNPs with low, 
medium and high heritability; respectively.  Here we see the same trend as in Figure 6 
through 8, the correlation peaks at 10 SNPs in both methods; however, the decrease in the 
correlation is much more rapid in the GRS method in comparison to the ensemble GRS 
method.  We also see that in Figure 11 when there is a phenotype with high heritability 
and high variability neither method performs well.  In Figure 9 through 11 we also show 
the bar plots of the number of SNPs in the most predictive model for the CV method.  We 
see that as the variability increases the accuracy of choosing the correct model as the 
most predictive model decreases.  In addition, in Figure 11 we see that when we simulate 
a phenotype with high heritability and high variability the accuracy of choosing the 
correct model is very poor.  In Figures 12 through 14 we show the boxplots of the 
correlation between the predicted and observed values for the GRS and ensemble GRS 
methods in which we simulated 30 causal SNPs with low, medium and high heritability; 
respectively.  From these plots we see that overall, the two methods show a similar peak 
correlation; however, after the inclusion of all the causal SNPs the correlation decreases 
quickly in the GRS method in comparison to the ensemble GRS method.  Once again we 
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see that the ensemble GRS model proves to be more robust to the inclusion of false 
positives in comparison to the GRS method; after all the causal SNPs are included in the 
prediction model the decrease in correlation is much more gradual.  As the variability of 
the phenotype increases we see that there is a decrease in prediction accuracy.  This is 
expected due to the fact that when the variability in the phenotype increases you expect to 
see more variability in your predictors.  In Figures 12 through 14 we also showed bar 
plots of the number of SNPs in the most predictive model for the CV method.  We see 
that oftentimes, the model that CV predicted to be the most predictive model included far 
less SNPs than the true model (the model including 30 SNPs). 
 
3.4 Prediction of HbF Results 
HbF is the major modifier of the clinical course of patients with sickle cell anemia 
(homozygosity for HBB glu6val) and β thalassemia. HbF inhibits sickle hemoglobin 
(HbS) polymerization and compensates for the deficit of normal HbA in β thalassemia 57.  
If it were possible to know at birth the HbF level likely to be present after stabilization of 
this measurement at about age 5 years 54, then a patient- specific prognosis might be 
given and HbF-inducing treatments better tailored to the individual. 
Here we show the results of phenotype prediction in sickle cell anemia (SCA) 
patients.  We used data from the Cooperative Study of Sickle Cell Disease (CSSCD) to 
generate GRS models of fetal hemoglobin (HbF) and then evaluated them in three 
validation cohorts: PUSH (N=77), Walk-PHaSST (N=181) and CData (N=127) 33; 40; 58.  
Previous GWAS of HbF in SCA patients have identified 3 main QTL involved in 
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phenotype regulation 54; 59; however, the aggregate effect of these QTL has yet to be 
examined.  Table 11 shows the patients characteristics of the four cohorts.  We see that 
the gender, hemoglobin and percent of patients with α thalassemia for similar across all 
the cohorts.  We see that the PUSH cohort has a younger group of patients while the 
Walk-PhaSST cohort has an older group of SCA patients.  We also see that the PUSH 
cohort has a higher average HbF level in comparison to the other cohorts.  The 
distribution of HbF levels (we use the cubic root transformation to maintain normality) in 
all four cohorts can be seen in Figure 15.  The distribution of age in the CSSCD, PUSH 
and Walk-PHaSST cohorts can be seen in Figure 16 (we did not have precise age 
information on subject in the C-Data).   
To examine heritability of HbF in the CSSCD population, we estimated the Pearson 
correlation of HbF levels between 64 sibling pairs that could be identified by identity by 
decent (IBD) analysis in PLINK using the genome-wide SNP data 34. As a comparison, 
we randomly sampled 200 unrelated pairs 1,000 times and computed average correlation 
between HbF levels of unrelated individuals.  The 64 sib pairs identified in the CSSCD 
had highly correlated values of HbF (r=0.693, pvalue=2.08x10-10) suggesting that HbF 
levels are heritable.  When randomly drawing 200 unrelated subjects where there was no 
correlation (average correlation, r=-0.022) (Figure 18).  The proportion of times the 
correlation of HbF between unrelated individuals was found to be significant (pvalue 
<.05) was .046. 
Figure 19 we see the results of the prediction accuracy of the HbF phenotype in SCA 
patients.  Here we see that when assessing the phenotype prediction accuracy with a GRS 
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model or 10 fold CV in three independent cohorts there is a lot of variability in model 
accuracy thus making it difficult to determine which prediction model provides the best 
prediction accuracy.  We also see that the best model is dependent upon which dataset we 
chose.  When using an ensemble of GRS models, the instability in the phenotype 
prediction accuracy is minimized.  In addition, if we include false positives in our 
prediction model or if we do not chose a prediction model that has the maximum 
correlation we do not lose that much variability explained in the phenotype due to the fact 
that we average the prediction error over multiple prediction models.  The correlation 
ranges between 0.2 and 0.4 for prediction with only 1 SNP, then peaks for models that 
include 10 to 15.  Inclusion of more than 50 SNPs decreases the correlation even further.  
While the inclusion of new SNPs in the GRS can have big effects on the predictive 
accuracy of the genetic risk model, as shown by the up and down pattern from one model 
to the next, the accuracy of the ensemble of these GRS models is more stable.  
 
An ensemble of the first 14 GRS models had the highest average correlation among all 
three data sets and explains 23.4% of the variability in HbF in the CSSCD cohort.  The 
proportion of variability explained in the ensemble of GRS models is found by 
computing the Pearson correlation between the predicted and observed values and then 
squaring the Pearson correlation.  The correlation between observed and predicted HbF 
using the ensemble of 14 GRS models was 0.44, 0.28 and 0.39 in the PUSH, Walk-
PHaSST and  C-Data cohorts, respectively.  Of these 14 SNPs, 5 were located 
in BCL11A; other SNPs were located in the olfactory receptor region on chromosome 
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11p15 and the site of the HBB gene cluster, and in the HBS1L-MYB interval on 
chromosome 6q. and were found previously to be associated with HbF 54; 59; 60. 
It is noticeable that the genetic risk models have consistently higher predictive 
accuracy in the PUSH cohort in comparison with the C-Data and Walk-PHaSST cohorts.  
When examining the age distributions across the cohorts, we see that the age distribution 
of the CSSCD and PUSH cohorts contain mainly children and young adolescents while 
the Walk-PHaSST cohort contains mainly adult patients (Figure 17).  We hypothesize 
that the genetic models predict more accurately in children and young adults. 
3.5 Discussion 
Here we introduced a novel method of genetic prediction of a continuous 
phenotype by computing an ensemble of GRS models.  We show through simulation and 
in an applied setting that the computation of an ensemble of GRS models yields a similar 
peak in prediction accuracy in comparison to the traditional GRS and 10 fold CV 
methods. We see that as the variability in the phenotype increases, the variability 
explained decreases; however, the robustness of the ensemble method remains.  
Due to the fact that determining the optimal number of SNPs for a GRS is 
difficult, the ensemble method is advantageous in that it is robust to the inclusion of false 
positives in comparison to the traditional GRS and 10 fold CV methods.  When 
predicting a continuous phenotype in an independent data set based on the GRS model 
from a training dataset we oftentimes see instability in prediction and irreproducible 
results (significant results in the GWAS from the training dataset not reproduced in test 
data set).  This instability causes a decrease in the explained variability of the phenotype.  
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Using an ensemble of GRS methods allows us to minimize this prediction error so that 
the decrease in the variability explained is minimized. As a result, if one were to not 
choose the best model, we would still achieve a high prediction accuracy since the 
amount of variability lost by including a few false positives is minimal. 
Prediction of HbF at an early age might help foresee some complications of sickle 
cell anemia and aid in optimizing its clinical management. Our goal was to identify 
methods that could combine SNPs to provide a higher predictive accuracy for foretelling 
HbF levels than single SNP analysis.  We use in our GRS SNPs with a MAF > 5%; 
however, as sickle cell anemia is a rare disease it is possible that some major genetic 
modifiers are rare variants with a lower allele frequency. Next generation sequencing 
might discover rare alleles that could be incorporated into a GRS to increase prediction 
accuracy.  It is important to note that we only predicted HbF levels for SCA patients of 
African descent as the training dataset used to build the GRS models was a cohort of 
SCA patients of African descent.  Genetic prediction can only be extended to ethnic 
populations in which the genetic variants that influence the phenotype are the same.  
Allelic variation may require that different SNPs be used to generate a GRS in different 
ancestry groups61. 
Incorporating information from multiple SNPs into an ensemble of GRS models 
increases the predictive accuracy and the percent variance in HbF levels explained in 
comparison to traditional GRS methods.  In an ensemble GRS, as few as 14 SNPs explain 
a larger fraction of the variability in HbF and better predicts HbF level when compared 
with single SNP analysis. In addition, an ensemble of genetic models that use varying 
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combinations of these 14 SNPs can predict HbF level with high accuracy.  Even though 
the predictive accuracy in the validation cohorts is high, it does not explain the totality of 
the variability in HbF that is due to heritability. This missing heritability could be due to 
gene-gene or gene-environment interactions 62, epigenetic factors, the common disease-
rare variant hypothesis 63, the possibility that inherited epigenetic factors cause 
resemblance between relatives 64; 65 or multiple rare variants with small effects that 
GWAS are poorly designed to detect 66.  Another reason for a portion of the unexplained 
variability could be due to the fact that the HbF measurements were measured using two 
different methods, alkali denaturation and high-pressure liquid chromatography.  This 
difference in measurement methods may be a potential confounder that limits the 
predictive accuracy of the model. 
Other studies have used GRS as a potential predictive tool.  A study of 3,575 
subjects from the Doetinchem Cohort Study computed a GRS to predict plasma total 
cholesterol levels which are highly genetically determined with a heritability estimated to 
be 40 to 60% 67; 68.  Using 12 SNPs they were able to explain 6.9% of the total variability 
in total cholesterol levels 69.  Participants in the Atherosclerosis Risk in Communities 
cohort of 10,745 individuals were used to construct a GRS of obesity in order to predict 
BMI 70-72.  The obesity GRS showed a correlation with BMI of r=0.12 for the unweighted 
GRS model and r=0.13 for the weighted model.  Our ensemble of GRS models of HbF is 
able to explain more phenotype variability and shows higher prediction accuracy in 
comparison to other potential predictive tools.  Using an ensemble of GRS models were 
able to explain 23.4% of the variability in HbF with a correlation ranging from 28 to 44% 
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in independent cohorts. A GRS has the potential to aid in predicting HbF levels and 
providing a more informed treatment plan for children where the HbF level does not 
stabilize until the age of 5 years 54. 
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Figure 6 Boxplots of Correlation versus Number of SNPs in Prediction Model with 5 
Causal SNPs and Low Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Figure 7 Boxplots of Correlation versus Number of SNPs in Prediction Model with 5 
Causal SNPs and Medium Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Figure 8 Boxplots of Correlation versus Number of SNPs in Prediction Model with 5 
Causal SNPs and High Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Figure 9 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
10 Causal SNPs and Low Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model. 
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Figure 10 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
10 Causal SNPs and Medium Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model. 
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Figure 11 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
10 Causal SNPs and High Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model. 
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Figure 12 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
30 Causal SNPs and Low Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Figure 13 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
30 Causal SNPs and Medium Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Figure 14 Boxplots of Correlation versus Number of SNPs in Prediction Model with 
30 Causal SNPs and High Heritability 
 
For the GRS and ensemble of GRS models we show the side-by-side boxplots of the 
number of SNPs in the model versus the correlation between the observed and predicted 
phenotype.  For the cross validation results we show bar plots of the number of SNPs in 
the most predictive model.  
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Table 11 Patient Characteristics for HbF Prediction 
 CSSCD 
(N=841) 
Mean (StD) 
PUSH 
(N=77) 
Mean (StD) 
Walk-
PHaSST 
(N=181) 
Mean (StD) 
C-Data 
(N=127) 
Mean 
(StD) 
Age (years) 17.19(10.69) 12.49 (4.69) 36.35 (12.54) 13-17 
Gender (% male) 53.7% 50.6% 51.9% 55.9% 
HbF (%) 6.65 (5.50) 9.81 (8.23)  6.07 (5.60) 7.59(5.09) 
Hemoglobin (d/mL) 8.42 (1.33) 8.62 (1.25) 8.50 (1.69) NA 
α thalassemia (% yes) 143 (31.4%) 21 (27.2%) 46 (25.4%) NA 
Patient characteristics for the CSSCD, PUSH, Walk-PHaSST and C-Data corts. 
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Figure 15 HbF Distributions for all Cohorts 
 
Histograms of the distribution of HbF for the CSSCD, Howard, Walk-PHaSST 
and CData cohorts. 
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Figure 16 Age Distribution of Subjects in HbF Analysis 
 
Histograms of the distribution of age for the CSSCD, Howard and Walk-PHaSST 
cohorts. 
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Figure 17 Heritability of HbF 
 
Left Panel: Scatterplot of HbF measurements for sibling pairs.  Right Panel: Scatterplot 
of HbF measurements for randomly selected unrelated pairs. 
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Figure 18 HbF Prediction Accuracy 
 
Scatterplot of the correlation between the observed and predicted values of HbF using a 
GRS model, an ensemble of GRS models and 10 fold CV.  
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4 Predicted Genetic Profiles 
4.1 Introduction 
The results of GWASs can be used to aid in phenotype prediction, disease 
classification and severity and to identify molecular pathways of disease.  Since 
oftentimes the use of one SNP does not explain a lot of the variability in phenotype, a 
common approach is to look at the combination of multiple SNPs (i.e. the computation of 
a GRS as seen in Chapter 3).  Here we introduce a novel approach to identifying SNPs 
that are important in prediction and identifying disease pathways.  We take the results of 
an unweighted GRS model (computation shown in Chapter 3) of HbF and use the 
predicted values of HbF as our genetic profile termed “predicted genetic profile” from the 
top unweighted GRS models.  We then cluster individuals’ predicted genetic profiles via 
an unsupervised correlation-based Bayesian hierarchical clustering algorithm (cluster 
analysis of gene expression dynamics, CAGED) 73.  We use the clustering results to 
determine which SNPs provide more influence for the phenotype cluster as a proxy to 
determine which SNPs may be more useful for HbF prediction and identification of 
disease pathways for SCA. 
  4.2 Methods 
To identify combinations of SNPs that are associated with extremes of HbF we 
conducted a cluster analysis of predicted HbF values as follows. The ensemble of genetic 
risk models with the first 20 GRS were used to compute a vector of predicted HbF values 
for each patient in the discovery set. These “predicted genetic profiles of HbF” provide 
information about the synergistic effect of increasing combination of multiple genetic 
84 
 
 
variants on HbF.  We analyzed the predicted genetic profiles via a Bayesian model based 
cluster analysis implemented in the CAGED software.   
The CAGED software uses a Bayesian model-based clustering method to cluster 
genetic profiles, which takes into account that the genetic profiles are not independent.  
The method is based on a general class of methods called Bayesian clustering by 
dynamics (BCD) 74.  BCD clusters two individuals together if their predicted genetic 
profiles are deemed to be generated by the same stochastic process.  The rationale of this 
approach is that individuals are allocated to the same cluster when they share the same 
predicted profile of HbF and thus should approximately share the same combination of 
genetic variants (genetic profile).  The Bayesian approach is thus to cluster predicted 
genetic profiles by searching for the most probable set of stochastic processes generating 
the predicted genetic profiles.  This method models predicted genetic profiles by 
autoregressive equations (Box GEP, Jenkins GM 1976) and groups together predicted 
genetic profiles with the highest probability of being generated by the same stochastic 
process.  In the method shown here, we use the Euclidean disease as a similarity measure 
to determine if two genetic profiles belong to the same cluster. 
We focused on 2 clusters of patients predicted to have the highest HbF levels and 
2 clusters of patients predicted to have the lowest HbF levels.  We computed the average 
number of risk alleles carried by patients allocated to these two clusters to determine the 
combinations of SNPs responsible for extremes of HbF.  We then validated the results by 
combining the three validation cohorts (Walk-PhaSST, Howard and C-Data described in 
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section 3.4) and running the cluster analysis to determine if the same combinations of 
SNPs were responsible for extreme levels of HbF.  
For additional validation of the cluster analysis, prevalence of avascular necrosis 
(AVN), acute chest syndrome (ACS), acute painful episodes of the patients in the two 
clusters were compared.  Standardized definitions of sub-phenotypes complications were 
used as described in Gaston et al. 198240. 
4.3 Results 
The cluster analysis of the CSSCD cohort automatically determined 44 clusters of 
4 to 35 SCA patients with similar predicted profiles of HbF.  Boxplots of HbF levels for 
CSSCD patients allocated to these clusters are shown in Figure 19 and highlight how 
different combinations of SNP genotypes can result in different distributions of HbF.  We 
examined the genetic profiles of individuals in clusters 43 and 44, predicted to have the 
highest HbF (10 individuals, average HbF 14.71) and clusters 1 and 25, predicted to have 
the lowest profiles (35 individuals, average HbF 2.57).  
Figures 21 and 22 show the predicted profiles of HbF for clusters deemed to have 
extremely high (clusters 43 and 44) and low (clusters 1 and 25) HbF levels.  The x axis 
shows the number of SNPs included in the GRS model and the y axis show the relative 
change in the predicted HbF as you add more SNPs to the model (i.e. a value greater than 
1 means that as you add one more SNP the predicted HbF increases, a value less than 1 
means that as you add one more SNP the predicted HbF decreases). 
Table 12 shows the average number of risk alleles for each genetic variant for 
those in the low and high HbF clusters in the CSSCD cohort.  To determine the variants 
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that have the most influence on the genetic profiles we examined which variants had the 
largest difference in prevalence between the low and high HbF clusters.  The variants that 
distinguish the low and high HbF clusters the most are rs2855039 (HBG1, HBG2); 
rs5006883, rs416586, rs10837814 of the olfactory receptor region and rs7113817 (Chr11; 
intergenic). 
To validate these results, we conducted a cluster analysis of the predicted using 
the top 20 GRS models in all subjects of the three replication cohorts to see if the genetic 
variants that were enriched in the low and high HbF cluster groups were similar to those 
of the CSSCD cohort.  The validation cohort was clustered into 25 clusters with sizes 
ranging from 2 to 41 patients.  Figure 20 shows the side by side boxplots of HbF levels 
for the genetic signature clusters in the validation cohorts.  Clusters 8, 20 and 22 were 
chosen to represent individuals with extremely low HbF (29 individuals, average HbF of 
2.77) values while clusters 25, 23 and 21 were chosen to represent individuals with 
higher HbF (27 individuals, average HbF of 7.79).  SNPs rs2855039 in HBG1, HBG2, 
rs7113817 in chr11 intergenic region and rs9525079 in chr13 intergenic region had a 
higher average number of risk alleles in the low HbF cluster in comparison with the high 
HbF cluster (Table 12). 
We hypothesized that the rate of the subphenotypes of HbF would be higher in the 
cluster with extremely low HbF in comparison to the cluster with extremely high HbF.  
Table 13 shows the results of the association between the high and low HbF clusters and 
the subphenotypes of sickle cell anemia like AVN, ACS and acute painful episodes.  The 
rate of having at least one pain episode is higher in the low HbF cluster versus the high 
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HbF cluster (91% versus 20%).  The AVN rate for those in the low HbF cluster is higher 
than those in the high HbF cluster (45% versus 20%).  The ACS rate for those in the low 
HbF cluster is slightly higher rate than those in the high HbF cluster (69% versus 60%).   
4.5 Discussion 
The genetic variants most associated with the genetic signatures clusters are those 
located in the olfactory receptor region.  This supports the hypothesis that extremely 
high/low levels of HbF is determined by an enrichment of genetic variants.  GWAS 
highlight SNPs that reach genome-wide significance (5E-08); however, examining the 
simultaneous effect of SNPs with a small or modest effect size can be used to distinguish 
between high and low HbF clusters.  SNPs that do not reach genome-wide significance 
may still be of biological importance when examining their joint effect.   
One of the advantages of GWAS is the ability to identify genetic variants that are 
associated with disease/a disease phenotype that could potentially be used for 
personalized medicine.  While some studies report the genetics does not explain more of 
the disease phenotype in comparison to clinical risk factors 15; 17; some of these studies 
involve phenotypes that are not strongly heritable and other studies only include SNPs 
that meet the genome-wide significance threshold.  Many studies are now showing that 
SNPs that do not meet the genome-wide level of significance still have value in 
phenotype prediction. 
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Figure 19 Boxplots of HbF levels by individuals assigned to different clusters based 
on the predicted profiles of HbF values 
 
Clusters are sorted by the median HbF value per cluster.   The boxes represent the range 
of HbF values for each cluster, the whiskers represent the minimum and maximum values 
of HbF for each cluster (minus outliers, which are represented as circles). 
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Figure 20 Boxplots of HbF levels of individuals assigned to different clusters based 
on the predicted profiles of HbF values (validation cohorts) 
 
Boxplots of the HbF level for each of the genetic signature clusters identified by the 
CAGED software for the validation cohorts. The boxes represent the range of HbF values 
for each cluster, the whiskers represent the minimum and maximum values of HbF for 
each cluster (minus outliers, which are represented as circles). 
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Figure 21 Predicted Profiles of HbF for those with High HbF 
 
These two plots show the predicted genetic profiles of HbF for individuals (each line is a 
person) in the two clusters with the highest average HbF in the CSSCD cohort (clusters 
43 and 44).  The x axis show the number of SNPs in the GRS and the y axis shows the 
relative change in HbF (i.e. a increase from 2 to 3 means that there is an increase in 
predicted HbF when you go from having 2 risk alleles to 3 risk alleles in the GRS). 
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Figure 22 Predicted Profiles of HbF for those with Low HbF 
 
These two plots show the predicted genetic profiles of HbF for the individuals (each line 
is a person) in the two clusters with the lowest average HbF in the CSSCD cohort 
(clusters 1 and 25).  The x axis show the number of SNPs in the GRS and the y axis 
shows the relative change in HbF (i.e. a decrease from 2 to 3 means that there is an 
decrease in predicted HbF when you go from having 2 risk alleles to 3 risk alleles in the 
GRS). 
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Table 12 Summary of genetic signatures 
SNP Gene CSSCD Validation Cohort 
Low 
HbF 
High 
HbF 
Difference Low 
HbF 
High HbF 
rs416586 OR51A 1.87 0.4 1.47 1.66 1.82 
rs10837814 OR51B2,OR51B3P 2 0.6 1.4 1.66 1.82 
rs2855039 HBG1, HBG2 2 0.7 1.3 1.62 0.55 
rs7113817 Chr 11; intergenic 1.87 0.8 1.07 1.52 0.09 
rs5006883 OR51B5,OR51B6 1.87 0.9 0.97 1.97 1.91 
rs6446085 Chr 6; intergenic 1.27 0.3 0.97 1.9 1.64 
rs9525079 Chr 13; intergenic 1.8 1.2 0.6 1.24 0.64 
rs10152034 Chr 14; intergenic 0.8 0.2 0.6 0.34 0.45 
rs11794652 FUBP3 1.2 0.6 0.6 1.83 1.36 
rs12469604 Chr 2; intergenic 1.8 1.4 0.4 0.38 0.55 
rs2021966 Chr 6; intergenic 1.47 1.1 0.37 1.97 1.36 
rs9494145 Chr 6; intergenic 1.93 1.6 0.33 1.52 1.73 
rs6932510 RPS6KA2 1.8 1.5 0.3 1.72 1.18 
rs2239580 COCH 0.37 0.1 0.27 0.79 1 
rs766432 BCL11A 1.87 1.6 0.27 1.83 2 
rs17114175 Chr 14; intergenic 0.33 0.1 0.23 1.72 1.91 
rs6732518 BCL11A 1.2 1.2 0 1.97 1.36 
rs10195871 BCL11A 1.33 1.4 -0.09 0.55 0.64 
rs6709302 BCL11A 0.07 0.5 -0.43 1.79 1.27 
rs6706648 BCL11A 0.07 0.8 -0.73 1.38 1.45 
 
The average number of risk alleles for each SNP is shown for the CSSCD and validation 
cohort stratified by the high and low HbF clusters.  The difference column shows the 
difference between the means of the low HbF and high HbF group. 
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Table 13 Subphenotype rates for low and high HbF clusters 
Subphenotype Low HbF 
(N=35) 
High HbF 
(N=10) 
Pain 32 (91%) 2 (20%) 
ACS 18 (69%)*  3 (60%)Ɨ 
AVN 16 (45%)  2 (20%) 
*There was only ACS information for 26 of the patients in the low HbF cluster 
ƗThere was only information for 5 of the patients in the high HbF cluster 
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5 Conclusions and Future Direction 
Identifying genetic variants associated with disease or disease severity is an 
important goal of GWAS.  Being able to use these genetic variants for phenotype 
prediction can have important clinical applications as it allows us to identify early on 
individuals who are at risk for disease or increased disease severity.  In this thesis, we 
present novel methods and an evaluation of methods to address issues associated with 
these goals of GWAS.  First, we present an evaluation of computing a summary 
phenotype using PCA and combining the results of multiple univariate GWAS to 
identifying genetic variants that are associated with multiple correlated traits.  We show 
that by using a PCA approach to create a summary phenotype and the 1st PC as a 
phenotype in a GWAS we have more power to detect an association with SNPs 
associated with multiple correlated traits in comparison to examining the intersection of 
results from multiple univariate GWAS. We show the power of the PCA approach in 
comparison of multiple univariate GWAS through simulation and through an applied 
setting by finding genetic variants associated with hemolysis in SCA patients.  Second, 
we develop a novel method for phenotype prediction of a continuous trait by computing 
an ensemble of genetic risk models. We show through prediction of HbF in SCA patients 
that using an ensemble of GRS models in comparison to using a GRS model is more 
robust to the inclusion of false positives and thus yields higher prediction accuracy.  We 
also show through simulation that an ensemble of GRS models is more robust to the 
inclusion of false positives in comparison to a GRS model and 10 fold CV.  Third, we 
develop a novel method of generating genetic profiles to identify genes involved in the 
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regulation of a continuous phenotype by generating “predicted genetic profiles”.   
Identifying genetic variants that are associated with a phenotype that is associated 
with multiple correlated traits can pose a major problem in the context of GWAS.  
Although genetic studies typically contain data collected on multiple traits, which are 
correlated, most GWAS analyses are performed on single traits.  There are several 
multivariate approaches that have been developed to account for the correlation between 
multiple traits in the context of GWAS.  The second chapter of this thesis compares two 
approaches to identifying genetic variants associated with a phenotypes that is associated 
with multiple correlated traits: creating a summary phenotype using a PCA, and 
examining the intersection of genetic variants from multiple univariate GWAS. 
The PCA approach involves using the 1st PC as a phenotype for the GWAS since 
it will explain the majority of the variability in comparison to the other PCs.  Another 
approach involves running a GWAS on each of the individual traits and examining the 
intersection of the genetic variants deemed significant in each univariate GWAS using a 
pre-defined threshold.  The drawbacks to the PCA approach are that if the 1st PC does not 
explain a lot of the variability of the correlated traits then it will be difficult to detect 
genetic variants that are associated with the correlated traits.  In addition, when using a 
PCA approach, it is difficult to interpret the results of the regression coefficients 
computed from the GWAS.  The drawbacks to examining the intersection of significant 
genetic variants from multiple univariate GWAS are that in an applied setting this 
method often yields few genetic variants.  Lowering the type I error rate threshold to 
include more genetic variants can cause the inclusion of false positives.  In the second 
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chapter of this thesis we show using simulations that the PCA approach is a more 
powerful approach to detect genetic variants in comparison to examining the intersection 
of multiple univariate GWAS.  We also show that these results are consistent regardless 
of whether or not the direction of effect from the additive model was in a consistent or 
not in a consistent direction.  These results also remained as we changed the variability of 
the phenotype from low to medium to high.  We then show in an applied setting that 
when trying to find genetic variants of hemolysis in SCA patients that using the PCA 
approach we are able to identify genetic variants that validate in multiple studies that 
would have been missed when examining the intersection of genetic variants deemed to 
be significant from multiple univariate GWAS.  When running a univariate GWAS there 
is more power to detect genetic variants that are trait specific; thus, when examining the 
intersection of these univariate GWAS there is very little overlap. 
In the third chapter, we show the development of a novel method of predicting a 
continuous phenotype by computing an ensemble of GRS models.  One of the issues that 
arises when using a GRS to predict a continuous phenotype is to determine the number of 
genetic variants that should be used to compute the GRS.  Oftentimes, there is instability 
in prediction from one GRS model to the next (the prediction accuracy will sharp 
increases and decreases) (Figure 8) making it difficult to identify which model has the 
highest prediction accuracy.  We show through simulation that by using an ensemble of 
GRS models the prediction accuracy is more robust to the inclusion of false positives in 
comparison to using a single GRS model or 10 fold CV; thus, if we include too many 
genetic variants we do not lose too much explained variability of the phenotype.  In an 
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applied setting we used the ensemble of GRS models to predict HbF in SCA patients.  
Due to the robustness of the ensemble method, the overall prediction accuracy was higher 
when using the ensemble of GRS models in comparison to a GRS model. 
In the fourth chapter we proposed a novel method of generating genetic risk 
profiles.  One of the drawbacks of GWAS is that oftentimes one SNP does not explain a 
lot of the variability in the phenotype; thus, it is useful to look at the effect of a 
combination of SNPs.  One of the approaches to examine the effect of multiple SNPs is 
to generate a genetic risk profile.  In this thesis we used the results of a GRS of HbF to 
compute predicted genetic profiles to examine the combined effect of multiple SNPs.  
The computation of the predicted genetic profiles consists of three steps:  
1) Use the top nested GRS models to compute predicted phenotypes (“predicted 
genetic profiles”). 
2) Cluster these “predicted genetic profiles” using a Bayesian hierarchical 
clustering algorithm implemented in the software CAGED. 
3) Extract the extreme clusters (those with extremely low and high HbF) to 
determine which SNPs provide more influence on the phenotype cluster. 
There are a number of possibilities for future research.  First, when evaluating the 
PCA summary phenotype approach to find genetic variants associated with multiple 
correlated traits it would be interesting to evaluate how well the approach worked when 
the correlation between the traits decreased in comparison to other multivariate 
approaches.  In addition, while we took into account the range of variability of our 
phenotype in our simulations, we did not examine what happens as the heritability of our 
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traits changes.  Second, when evaluating the ensemble of GRS methods to predict a 
continuous phenotype, we did not examine how well the approach works with a complex 
trait.  For example, it would be interesting to see how well the approach would work 
when the phenotype is one that is influenced by multiple correlated traits (i.e. using a 
summary phenotype derived from a PCA).  In addition, the method of ensemble GRS 
could be extended to incorporate ancestry so that perhaps we may be better able to 
predict more admixed populations (for the prediction of HbF we looked solely at 
African/African American SCA patients).  Third, we did not compare the approach of 
clustering “predicted genetic profiles” using CAGED to other clustering methods (i.e. 
hierarchical clustering, k-means clustering). 
The advent of next generation sequencing will have an impact on all of the 
evaluations performed and methods developed in this thesis.  It is already known that 
typical GWAS methods do not have sufficient power to detect genetic variants when the 
variant is rare and can yield false positive results.  Thus, identifying rare genetic variants 
that are associated with multiple correlated traits will prove to be a challenge.  We will 
also have to determine ways to incorporate rare genetic variants into phenotype 
prediction models and genetic risk profiles. 
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